maneb - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	maneb	go back to main search page
Accession:	CHEBI:52497	browse the term
Definition:	A polymeric complex of manganese with the ethylene bis(dithiocarbamate) anionic ligand. An agrochemical fungicide, it is used to control a variety of diseases including blight, leaf spot, rust, downy mildew and scab.
Synonyms:	exact_synonym:	[{2-[(sulfanylcarbothioyl)amino]ethyl}carbamodithioato(2-)-kappa(2)S,S']manganese
	related_synonym:	Formula=(C4H6MnN2S4)n; manganese ethane-1,2-diyldicarbamodithioate
	xref:	Beilstein:3747585; CAS:12427-38-2; KEGG:C15231
	xref_mesh:	MESH:D008344
	xref:	PMID:18605226; PMID:20188092; PMID:20430411; PMID:21314462; PMID:21402726; PMID:23764462; PMID:24936438; PMID:25275677; PPDB:426; Pesticides:maneb; Reaxys:3747585; Wikipedia:Maneb

show annotations for term's descendants Sort by:
Rat (999) Mouse (1022) Human (1016) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (999)

maneb

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AP2 associated kinase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AAK1 mRNA

NCBI chr 4:119,300,128...119,451,834
Ensembl chr 4:119,295,257...119,450,969

G

aminoadipate-semialdehyde synthase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AASS mRNA

NCBI chr 4:51,606,461...51,663,136
Ensembl chr 4:51,606,462...51,663,136

G

4-aminobutyrate aminotransferase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ABAT mRNA

NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835

G

ATP binding cassette subfamily A member 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ABCA2 mRNA

NCBI chr 3:8,244,515...8,264,545
Ensembl chr 3:8,244,639...8,264,537

G

ATP binding cassette subfamily A member 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ABCA5 mRNA

NCBI chr10:95,240,159...95,309,195
Ensembl chr10:95,240,154...95,308,976

G

ATP binding cassette subfamily D member 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ABCD2 mRNA

NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642

G

abhydrolase domain containing 8

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ABHD8 mRNA

NCBI chr16:18,144,464...18,151,201
Ensembl chr16:18,144,464...18,157,667

G

abl-interactor 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ABI2 mRNA

NCBI chr 9:61,827,186...61,905,703
Ensembl chr 9:61,827,139...61,905,699

G

ABI family member 3 binding protein

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ABI3BP mRNA

NCBI chr11:43,912,187...44,128,888
Ensembl chr11:43,913,043...44,128,929

G

actin binding LIM protein family, member 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ABLIM2 mRNA

NCBI chr14:74,865,409...74,990,334
Ensembl chr14:74,866,281...74,990,334

G

acyl-CoA dehydrogenase short chain

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA]

NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898

G

angiotensin I converting enzyme

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ACE mRNA

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

acetylcholinesterase

decreases expression
multiple interactions

Maneb results in decreased expression of ACHE protein
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA

PMID:3868355 PMID:23017109

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

aconitase 2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of ACO2 mRNA

NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ACSL4 mRNA

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

actin-like 6B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ACTL6B mRNA

NCBI chr12:19,124,887...19,141,419
Ensembl chr12:19,124,916...19,141,376

G

adenosine deaminase-like

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MAPDA mRNA

NCBI chr 3:108,101,857...108,119,557
Ensembl chr 3:108,101,857...108,118,516
Ensembl chr 3:108,101,857...108,118,516

G

ADAM metallopeptidase domain 11

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ADAM11 mRNA

NCBI chr10:87,724,115...87,742,773
Ensembl chr10:87,724,234...87,741,562

G

ADAM metallopeptidase domain 22

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of ADAM22 mRNA

NCBI chr 4:25,716,055...25,970,932
Ensembl chr 4:25,715,990...25,964,962

G

adenosine deaminase, RNA-specific

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ADAR mRNA

NCBI chr 2:175,138,391...175,178,280
Ensembl chr 2:175,138,403...175,178,282

G

adenylate cyclase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ADCY2 mRNA

NCBI chr 1:34,375,639...34,822,252
Ensembl chr 1:34,375,895...34,822,236

G

adhesion G protein-coupled receptor B1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ADGRB1 mRNA

NCBI chr 7:106,404,827...106,476,902
Ensembl chr 7:106,404,958...106,476,902

G

adhesion G protein-coupled receptor B2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ADGRB2 mRNA

NCBI chr 5:142,299,190...142,362,540
Ensembl chr 5:142,331,329...142,362,540

G

adhesion G protein-coupled receptor G1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of ADGRG1 mRNA

NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108

G

adhesion G protein-coupled receptor L3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ADGRL3 mRNA

NCBI chr14:26,336,320...27,104,060
Ensembl chr14:26,368,277...27,105,860

G

adrenomedullin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

adenosine A1 receptor

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ADORA1 mRNA

NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801

G

adenosine A2a receptor

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ADORA2A mRNA

NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386

G

ALF transcription elongation factor 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AFF3 mRNA

NCBI chr 9:40,399,099...40,856,716
Ensembl chr 9:40,404,375...40,857,247

G

AFG3 like matrix AAA peptidase subunit 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AFG3L2 mRNA

NCBI chr18:60,954,268...60,999,110
Ensembl chr18:60,954,268...60,999,110

G

argonaute RISC catalytic component 3

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of AGO3 mRNA

NCBI chr 5:138,632,367...138,714,230
Ensembl chr 5:138,639,569...138,714,230

G

allograft inflammatory factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of AIF1 protein; [Paraquat co-treated with Maneb] results in increased expression of AIF1 protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of AIF1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of AIF1 protein]

PMID:28202386 PMID:32375810

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

adherens junctions associated protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AJAP1 mRNA

NCBI chr 5:163,907,846...164,021,004
Ensembl chr 5:163,907,847...164,020,317

G

adenylate kinase 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AK5 mRNA

NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458

G

aldo-keto reductase family 1 member B1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of AKR1B1 mRNA

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

AKT serine/threonine kinase 1

multiple interactions

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of AKT1 protein; [alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of AKT1 protein; [Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA]

PMID:19883720 PMID:23963992

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

5'-aminolevulinate synthase 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of ALAS2 mRNA

NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519

G

albumin

increases secretion

Maneb results in increased secretion of ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 2 family member

decreases activity
multiple interactions

Maneb results in decreased activity of ALDH2 protein
[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein

PMID:17010440 PMID:34830855

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

aldehyde dehydrogenase 5 family, member A1

decreases activity
multiple interactions

Maneb results in decreased activity of ALDH5A1 protein
[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA]

PMID:17010440 PMID:23963992

NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677

G

aldolase, fructose-bisphosphate C

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of ALDOC mRNA

NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066

G

alsin Rho guanine nucleotide exchange factor ALS2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ALS2 mRNA

NCBI chr 9:60,613,182...60,686,394
Ensembl chr 9:60,613,167...60,670,737

G

adhesion molecule with Ig like domain 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AMIGO2 mRNA

NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695

G

amnion associated transmembrane protein

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of AMN mRNA

NCBI chr 6:130,311,372...130,318,815
Ensembl chr 6:130,311,372...130,318,815

G

adenosine monophosphate deaminase 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AMPD3 mRNA

NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887

G

angel homolog 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ANGEL1 mRNA

NCBI chr 6:106,349,125...106,386,202
Ensembl chr 6:106,349,126...106,386,209

G

ankyrin repeat domain 13D

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ANKRD13D mRNA

NCBI chr 1:201,565,712...201,577,987
Ensembl chr 1:201,565,712...201,577,933

G

ankyrin repeat domain containing 26

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ANKRD26 mRNA

NCBI chr 4:151,670,604...151,740,032
Ensembl chr 4:151,672,037...151,739,968

G

ankyrin repeat and sterile alpha motif domain containing 1B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ANKS1B mRNA

NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:24,312,843...25,477,693

G

anoctamin 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ANO3 mRNA

NCBI chr 3:97,235,671...97,550,090
Ensembl chr 3:97,238,354...97,550,154

G

adaptor related protein complex 3 subunit beta 2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of AP3B2 mRNA

NCBI chr 1:135,412,580...135,445,191
Ensembl chr 1:135,412,580...135,445,191

G

adaptor related protein complex 3 subunit delta 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of AP3D1 mRNA

NCBI chr 7:8,970,249...9,005,651
Ensembl chr 7:8,970,291...9,005,643

G

amyloid beta precursor protein binding family B member 1

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of APBB1 mRNA

NCBI chr 1:159,896,889...159,920,505
Ensembl chr 1:159,896,880...159,920,627

G

activity-regulated cytoskeleton-associated protein

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ARC mRNA

NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378

G

ADP-ribosylation factor 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ARF3 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of ARF3 mRNA

PMID:18386188 PMID:36117858

NCBI chr 7:129,886,082...129,912,022
Ensembl chr 7:129,886,082...129,912,002

G

arginase 1

decreases expression
multiple interactions

Maneb results in decreased expression of ARG1 mRNA
[Maneb co-treated with Paraquat] results in increased expression of ARG1 mRNA; [Paraquat co-treated with Maneb] results in increased expression of ARG1 mRNA; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ARG1 mRNA]

PMID:29568078 PMID:32194361 PMID:32375810 PMID:34052309

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

Rho GTPase activating protein 26

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ARHGAP26 mRNA

NCBI chr18:30,835,806...31,237,945
Ensembl chr18:30,838,671...31,235,194

G

Rho GTPase activating protein 32

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ARHGAP32 mRNA

NCBI chr 8:30,421,269...30,681,653
Ensembl chr 8:30,421,515...30,678,454

G

Rho GTPase activating protein 44

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ARHGAP44 mRNA

NCBI chr10:49,655,583...49,822,876
Ensembl chr10:49,655,584...49,824,297

G

ADP-ribosylation factor like GTPase 5A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ARL5A mRNA

NCBI chr 3:36,878,461...36,903,362
Ensembl chr 3:36,880,712...36,903,211

G

aryl hydrocarbon receptor nuclear translocator 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ARNT2 mRNA

NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153

G

aristaless related homeobox

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ARX mRNA

NCBI chr X:58,016,233...58,028,149
Ensembl chr X:58,016,233...58,028,142

G

N-acylsphingosine amidohydrolase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ASAH2 mRNA

NCBI chr 1:229,865,662...229,973,253
Ensembl chr 1:229,865,662...229,939,162

G

activating signal cointegrator 1 complex subunit 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ASCC1 mRNA

NCBI chr20:27,941,053...28,031,272
Ensembl chr20:27,941,283...28,031,272

G

achaete-scute family bHLH transcription factor 1

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ASCL1 mRNA

NCBI chr 7:21,903,136...21,906,003
Ensembl chr 7:21,903,126...21,905,993

G

asporin

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ASPN mRNA

NCBI chr17:15,079,910...15,104,369
Ensembl chr17:15,080,639...15,104,041

G

ATPase family, AAA domain containing 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ATAD2 mRNA

NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738

G

activating transcription factor 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

autophagy related 12

multiple interactions

Maneb promotes the reaction [Paraquat results in increased expression of ATG12 protein]

NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418

G

autophagy related 16-like 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ATG16L2 mRNA

NCBI chr 1:155,687,386...155,703,419
Ensembl chr 1:155,684,564...155,703,420

G

atos homolog A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FAM214A mRNA

NCBI chr 8:75,694,828...75,772,565
Ensembl chr 8:75,695,022...75,772,549

G

ATP synthase F1 subunit alpha

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ATP5F1A protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP5F1A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP5F1A protein]

NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794

G

ATP synthase membrane subunit c locus 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of ATP5MC1 mRNA

NCBI chr10:81,024,056...81,026,780
Ensembl chr10:81,023,925...81,027,124
Ensembl chr10:81,023,925...81,027,124

G

ATPase H+ transporting V0 subunit B

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of ATP6V0B mRNA

NCBI chr 5:131,423,384...131,424,900
Ensembl chr 5:131,423,387...131,426,401

G

ATPase H+ transporting V0 subunit C

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of ATP6V0C mRNA

NCBI chr10:13,196,204...13,202,580
Ensembl chr10:13,196,204...13,201,500

G

ATPase H+ transporting V1 subunit C1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA]

NCBI chr 7:69,834,464...69,872,278
Ensembl chr 7:69,834,463...69,872,278

G

ATPase phospholipid transporting 8A2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of ATP8A2 mRNA

NCBI chr15:33,817,309...34,350,193
Ensembl chr15:33,819,755...34,350,223

G

ataxin 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ATXN1 mRNA

NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360

G

apoptosis and caspase activation inhibitor

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of AVEN mRNA

NCBI chr 3:99,299,009...99,431,635
Ensembl chr 3:99,298,930...99,431,634

G

Beta-1,3-galactosyltransferase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of B3GALT1 mRNA

NCBI chr 3:52,253,413...52,826,508
Ensembl chr 3:52,253,618...52,825,313

G

Beta-1,3-galactosyltransferase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of B3GALT2 mRNA

NCBI chr13:55,389,406...55,398,419
Ensembl chr13:55,389,406...55,398,419

G

beta-1,3-glucuronyltransferase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of B3GAT2 mRNA

NCBI chr 9:26,167,174...26,250,153
Ensembl chr 9:26,167,174...26,250,153

G

beta-1,4-galactosyltransferase 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of B4GALT5 mRNA

NCBI chr 3:156,018,056...156,033,983
Ensembl chr 3:156,018,053...156,070,074

G

BAH domain and coiled-coil containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BAHCC1 mRNA

NCBI chr10:105,526,309...105,583,320
Ensembl chr10:105,522,172...105,583,317

G

BCL2-antagonist/killer 1

multiple interactions
increases expression
affects response to substance

[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA]
[Paraquat co-treated with Maneb] results in increased expression of BAK1 protein; Maneb inhibits the reaction [BAK1 protein affects the susceptibility to Paraquat]; Paraquat inhibits the reaction [BAK1 protein affects the susceptibility to Maneb]
Maneb results in increased expression of BAK1 mRNA; Maneb results in increased expression of BAK1 protein

PMID:18266926 PMID:23963992

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

[Paraquat co-treated with Maneb] results in increased expression of BAX protein; BAX protein affects the susceptibility to [Paraquat co-treated with Maneb]
Maneb results in increased expression of BAX protein
[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA; [Paraquat co-treated with Maneb] results in increased expression of BAX protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein]

PMID:18266926 PMID:20964710 PMID:23963992

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

increases expression
multiple interactions

Maneb results in increased expression of BBC3 protein
3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BBC3 protein]; [Paraquat co-treated with Maneb] results in increased expression of BBC3 protein; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BBC3 protein]

PMID:18266926 PMID:34897981

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCAS3, microtubule associated cell migration factor

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of BCAS3 mRNA

NCBI chr10:70,213,710...70,673,080
Ensembl chr10:70,214,098...70,673,080

G

branched chain amino acid transaminase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BCAT1 mRNA

NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597

G

branched chain keto acid dehydrogenase E1 subunit beta

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BCKDHB mRNA

NCBI chr 8:84,845,264...85,027,812
Ensembl chr 8:84,845,264...85,027,812

G

BCL11 transcription factor A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BCL11A mRNA

NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180

G

BCL2, apoptosis regulator

multiple interactions
increases expression

[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA]
Maneb results in increased expression of BCL2 mRNA; Maneb results in increased expression of BCL2 protein

PMID:18266926 PMID:23963992 PMID:36117858

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL2-related protein A1

increases expression
multiple interactions

Maneb results in increased expression of BCL2A1 mRNA
[Paraquat co-treated with Maneb] results in increased expression of BCL2A1 protein

NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998

G

Bcl2-like 1

increases expression

Maneb results in increased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

Bcl2-like 11

increases expression
multiple interactions

Maneb results in increased expression of BCL2L11 protein
[Paraquat co-treated with Maneb] results in increased expression of BCL2L11 protein

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

brain-derived neurotrophic factor

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BDNF mRNA
[Paraquat co-treated with Maneb] results in decreased expression of BDNF mRNA; [Paraquat co-treated with Maneb] results in decreased expression of BDNF protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of BDNF mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of BDNF protein]

PMID:23017109 PMID:27460631 PMID:33368748 PMID:36117858

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

beclin 1

increases expression
multiple interactions

Maneb results in increased expression of BECN1 protein
[Paraquat co-treated with Maneb] results in increased expression of BECN1 protein

PMID:22292029 PMID:26884967

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

BEN domain containing 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BEND7 mRNA

NCBI chr17:73,483,212...73,566,221
Ensembl chr17:73,485,282...73,567,559

G

brain expressed X-linked 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BEX1 mRNA

NCBI chr X:99,219,014...99,220,518
Ensembl chr X:99,219,014...99,220,958

G

BICD cargo adaptor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BICD1 mRNA; [Paraquat co-treated with Maneb] affects the expression of BICD1 mRNA

PMID:22563483 PMID:36117858

NCBI chr 4:182,479,071...182,631,504
Ensembl chr 4:182,479,071...182,627,434

G

BICRA like chromatin remodeling complex associated protein

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BICRAL mRNA

NCBI chr 9:14,100,253...14,185,368
Ensembl chr 9:14,154,209...14,183,671

G

BH3 interacting domain death agonist

increases expression
multiple interactions

Maneb results in increased expression of BID protein
[Maneb co-treated with Paraquat] results in increased expression of BID protein

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

BCL2-interacting killer

increases expression
multiple interactions

Maneb results in increased expression of BIK mRNA; Maneb results in increased expression of BIK protein
[Paraquat co-treated with Maneb] results in increased expression of BIK protein

NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296

G

bridge-like lipid transfer protein family member 3B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of UHRF1BP1L mRNA

NCBI chr 7:24,181,635...24,261,720
Ensembl chr 7:24,181,644...24,261,720

G

bone morphogenetic protein 2

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP2 mRNA

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein 4

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

base methyltransferase of 25S rRNA 2 homolog

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of SAMTOR mRNA

NCBI chr 4:41,881,630...41,945,472
Ensembl chr 4:41,879,993...41,945,539

G

BCL2 interacting protein 3

increases expression

Maneb results in increased expression of BNIP3 mRNA; Maneb results in increased expression of BNIP3 protein

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

BCL2 interacting protein 3 like

increases expression

Maneb results in increased expression of BNIP3L mRNA

NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803

G

B-Raf proto-oncogene, serine/threonine kinase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BRAF mRNA

NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463

G

BRF1, RNA polymerase III transcription initiation factor subunit

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of BRF1 mRNA

NCBI chr 6:132,034,378...132,081,313
Ensembl chr 6:132,037,272...132,081,278

G

BR serine/threonine kinase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BRSK2 mRNA

NCBI chr 1:197,035,505...197,088,624
Ensembl chr 1:197,035,633...197,088,092

G

BTB domain containing 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of BTBD3 mRNA; [Maneb co-treated with Paraquat] results in increased expression of BTBD3 mRNA

NCBI chr 3:125,591,427...125,621,660
Ensembl chr 3:125,591,490...125,619,038

G

C1q and TNF related 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of C1QTNF4 mRNA

NCBI chr 3:76,854,368...76,872,991
Ensembl chr 3:76,857,735...76,874,139

G

C2 calcium-dependent domain containing 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of C2CD5 mRNA

NCBI chr 4:175,969,544...176,055,597
Ensembl chr 4:175,969,545...176,055,558

G

calcium voltage-gated channel subunit alpha1 C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CACNA1C mRNA

NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648

G

calcium voltage-gated channel subunit alpha1 E

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CACNA1E mRNA

NCBI chr13:66,574,659...67,063,443
Ensembl chr13:66,581,920...66,894,450

G

calcium voltage-gated channel auxiliary subunit beta 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CACNB2 mRNA

NCBI chr17:77,564,630...77,910,000
Ensembl chr17:77,564,460...77,909,106

G

calcium voltage-gated channel auxiliary subunit gamma 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CACNG4 mRNA

NCBI chr10:92,683,778...92,745,842
Ensembl chr10:92,683,761...92,746,126

G

calcyclin binding protein

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of CACYBP mRNA

NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177

G

calcium dependent secretion activator 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CADPS2 mRNA

NCBI chr 4:51,780,415...52,309,641
Ensembl chr 4:51,781,053...52,309,829

G

calbindin 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CALB2 mRNA

NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438

G

calmodulin 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA]

NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227

G

calmodulin 2

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of CALM2 mRNA

NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
Ensembl chr15:7,091,567...7,104,287

G

calneuron 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CALN1 mRNA

NCBI chr12:25,811,743...26,303,670
Ensembl chr12:25,819,628...26,303,344

G

calcium/calmodulin-dependent protein kinase IV

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CAMK4 mRNA; [Maneb co-treated with Paraquat] results in increased expression of CAMK4 mRNA

NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487

G

cathelicidin antimicrobial peptide

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CAMP mRNA
[Paraquat co-treated with Maneb] results in decreased expression of CAMP mRNA

PMID:22563483 PMID:27460631

NCBI chr 8:109,841,729...109,843,543
Ensembl chr 8:109,841,729...109,843,543

G

calpain 11

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CAPN11 mRNA

NCBI chr 9:15,344,059...15,365,604
Ensembl chr 9:15,344,089...15,365,601

G

calpain 15

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CAPN15 mRNA

NCBI chr10:14,972,807...14,999,411
Ensembl chr10:14,972,800...14,999,508

G

carbonic anhydrase 14

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CAR14 mRNA

NCBI chr 2:183,442,263...183,449,231
Ensembl chr 2:183,441,667...183,449,693

G

carbonic anhydrase 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CAR7 mRNA

NCBI chr19:429,063...438,478
Ensembl chr19:429,075...438,467

G

capping protein regulator and myosin 1 linker 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CARMIL3 mRNA

NCBI chr15:28,978,440...28,995,865
Ensembl chr15:28,979,007...28,996,225

G

caspase 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased cleavage of CASP1 protein; [Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA; [Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased cleavage of CASP1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA]

PMID:23963992 PMID:32375810 PMID:34052309

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

increases activity
multiple interactions

Maneb results in increased activity of CASP3 protein
3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form]; [Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form]; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form]

PMID:22824503 PMID:34897981

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

increases activity

Maneb results in increased activity of CASP7 protein

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

increases activity

Maneb results in increased activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases activity

[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA; [Paraquat co-treated with Maneb] results in increased expression of CASP9 protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein]
Maneb results in increased activity of CASP9 protein

PMID:20964710 PMID:22824503 PMID:23963992

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

calsequestrin 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CASQ2 mRNA

NCBI chr 2:189,526,003...189,582,276
Ensembl chr 2:189,525,960...189,582,267

G

cytosolic arginine sensor for mTORC1 subunit 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GATSL2 mRNA

NCBI chr12:22,577,504...22,620,182
Ensembl chr12:22,577,512...22,620,182

G

catalase

decreases activity
multiple interactions

Maneb results in decreased activity of CAT protein
[Maneb co-treated with Paraquat] results in increased expression of CAT mRNA

PMID:26210702 PMID:28322069 PMID:29859004

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

coiled-coil domain containing 148

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CCDC148 mRNA

NCBI chr 3:43,356,885...43,631,999
Ensembl chr 3:43,356,892...43,631,991

G

coiled-coil domain containing 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CCDC6 mRNA

NCBI chr20:18,432,177...18,528,186
Ensembl chr20:18,433,695...18,528,658

G

coiled coil domain containing 88A

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CCDC88A mRNA

NCBI chr14:103,104,091...103,256,112
Ensembl chr14:103,103,513...103,252,368

G

coiled-coil domain containing 88C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CCDC88C mRNA

NCBI chr 6:120,169,752...120,289,459
Ensembl chr 6:120,169,738...120,289,555

G

coiled-coil domain containing 92

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CCDC92 mRNA

NCBI chr12:31,796,102...31,823,333
Ensembl chr12:31,796,684...31,823,337

G

cholecystokinin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CCK mRNA

NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084

G

C-C motif chemokine ligand 19

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CCL19 mRNA

NCBI chr 5:56,963,364...56,965,308
Ensembl chr 5:56,963,364...56,965,308

G

C-C motif chemokine ligand 21

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CCL21 mRNA; [Paraquat co-treated with Maneb] affects the expression of CCL21A mRNA

NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686

G

cyclin D1

multiple interactions

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of CCND1 protein
[Maneb co-treated with Paraquat] results in decreased expression of CCND1 mRNA

PMID:19883720 PMID:29859004

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CCND2 mRNA

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

centriolar coiled-coil protein 110

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CCP110 mRNA

NCBI chr 1:173,042,238...173,072,873
Ensembl chr 1:173,042,310...173,072,873

G

CD24 molecule

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CD24A mRNA

NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662

G

CD34 molecule

increases expression

Maneb results in increased expression of CD34

NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832

G

Cd68 molecule

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of CD68 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CD68 mRNA]

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

cell division cycle associated 7

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CDCA7 mRNA

NCBI chr 3:57,322,718...57,333,353
Ensembl chr 3:57,322,708...57,333,353

G

cadherin 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CDH7 mRNA

NCBI chr13:26,672,058...26,821,571
Ensembl chr13:26,672,484...26,819,846

G

cadherin-related family member 4

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CDHR4 mRNA

NCBI chr 8:108,682,594...108,690,358
Ensembl chr 8:108,682,613...108,690,367

G

CDP-diacylglycerol--inositol 3-phosphatidyltransferase

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of CDIPT mRNA

NCBI chr 1:181,583,098...181,587,409
Ensembl chr 1:181,583,141...181,587,408

G

cyclin dependent kinase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA]

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 5 regulatory subunit 1

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5R1 mRNA

NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456

G

CDK5 regulatory subunit associated protein 1

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5RAP1 mRNA

NCBI chr 3:142,838,081...142,872,669
Ensembl chr 3:142,708,028...142,872,677

G

CDK5 regulatory subunit associated protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA; LRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]; SNCA protein inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]

NCBI chr 5:83,792,282...83,961,129
Ensembl chr 5:83,792,284...83,960,782

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CDKN1A mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDKN1A mRNA]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2A

multiple interactions
increases expression

[Maneb co-treated with Paraquat] results in increased expression of CDKN2A mRNA
Maneb results in increased expression of CDKN2A mRNA

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

cysteine dioxygenase type 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CDO1 mRNA

NCBI chr18:39,432,473...39,447,253
Ensembl chr18:39,432,474...39,447,296

G

CDP-diacylglycerol synthase 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CDS1 mRNA

NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681

G

CCAAT/enhancer binding protein delta

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CEBPD mRNA

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

CUGBP, Elav-like family member 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CELF3 mRNA

NCBI chr 2:182,116,034...182,130,163
Ensembl chr 2:182,116,073...182,130,163

G

cell cycle exit and neuronal differentiation 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CEND1 mRNA

NCBI chr 1:196,525,153...196,528,152
Ensembl chr 1:196,523,920...196,528,302

G

centromere protein C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CENPC1 mRNA

NCBI chr14:21,988,067...22,046,732
Ensembl chr14:21,988,144...22,055,476

G

centrosomal protein 290

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of CEP290 mRNA

NCBI chr 7:35,310,071...35,399,388
Ensembl chr 7:35,310,199...35,399,392

G

centrosomal protein 295

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CEP295 mRNA

NCBI chr 8:12,156,568...12,194,542
Ensembl chr 8:12,156,554...12,194,552

G

cerebral endothelial cell adhesion molecule

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CERCAM mRNA

NCBI chr 3:13,118,150...13,155,960
Ensembl chr 3:13,142,107...13,155,956

G

chromatin assembly factor 1 subunit A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CHAF1A mRNA

NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654

G

chromogranin A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CHGA mRNA

NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398

G

chondroitin polymerizing factor 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CHPF2 mRNA

NCBI chr 4:10,578,470...10,585,940
Ensembl chr 4:10,580,462...10,585,916

G

chordin-like 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CHRDL1 mRNA

NCBI chr X:106,889,125...106,992,937
Ensembl chr X:106,889,125...106,992,921

G

cholinergic receptor, muscarinic 2

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CHRM2 mRNA

NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions

[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein]

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

circadian associated repressor of transcription

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CIART mRNA

NCBI chr 2:183,419,819...183,424,845
Ensembl chr 2:183,419,819...183,423,313

G

ciliary microtubule associated protein 1B

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ODF3B mRNA

NCBI chr 7:120,444,232...120,447,294
Ensembl chr 7:120,444,232...120,446,749

G

cold inducible RNA binding protein

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of CIRBP mRNA

NCBI chr 7:9,533,857...9,538,899
Ensembl chr 7:9,424,178...9,538,818

G

creatine kinase, mitochondrial 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CKMT1 mRNA

NCBI chr 3:108,329,859...108,335,760
Ensembl chr 3:108,330,705...108,335,758

G

CDC28 protein kinase regulatory subunit 1B

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CKS1B mRNA

NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636

G

chloride channel accessory 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CLCA1 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CLCA1 mRNA]

NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369

G

chloride voltage-gated channel 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CLCN5 mRNA

NCBI chr X:15,185,380...15,339,977
Ensembl chr X:15,185,451...15,334,264

G

chloride voltage-gated channel 7

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CLCN7 mRNA

NCBI chr10:14,151,758...14,177,130
Ensembl chr10:14,151,758...14,177,130

G

claudin 12

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CLDN12 mRNA

NCBI chr 4:28,522,659...28,533,647
Ensembl chr 4:28,522,678...28,533,801

G

C-type lectin domain containing 16A

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CLEC16A mRNA

NCBI chr10:4,927,799...5,123,749
Ensembl chr10:4,928,030...5,123,578

G

CAP-GLY domain containing linker protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CLIP2 mRNA

NCBI chr12:22,163,044...22,227,023
Ensembl chr12:22,163,218...22,227,023

G

CAP-GLY domain containing linker protein family, member 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CLIP4 mRNA

NCBI chr 6:23,616,280...23,697,625
NCBI chr 6:23,718,580...23,729,231
NCBI chr 6:23,597,729...23,601,000
Ensembl chr 6:23,616,281...23,677,874

G

CXADR-like membrane protein

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CLMP mRNA

NCBI chr 8:41,060,527...41,168,841
Ensembl chr 8:41,060,799...41,168,838

G

clusterin

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of CLU mRNA

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

carboxymethylenebutenolidase homolog

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CMBL mRNA

NCBI chr 2:82,569,257...82,591,007
Ensembl chr 2:82,571,888...82,591,009

G

cornichon family AMPA receptor auxiliary protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CNIH2 mRNA

NCBI chr 1:202,399,416...202,405,110
Ensembl chr 1:202,399,419...202,405,089

G

cornichon family AMPA receptor auxiliary protein 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CNIH3 mRNA

NCBI chr13:93,016,707...93,208,168
Ensembl chr13:93,099,784...93,208,121

G

centrobin, centriole duplication and spindle assembly protein

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CNTROB mRNA

NCBI chr10:54,022,523...54,047,793
Ensembl chr10:54,022,852...54,044,849

G

collagen type XIV alpha 1 chain

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of COL14A1 mRNA

NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214

G

collagen type I alpha 1 chain

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

COPI coat complex subunit epsilon

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of COPE mRNA

NCBI chr16:19,114,871...19,125,076
Ensembl chr16:19,114,871...19,128,907

G

cytochrome c oxidase subunit 5A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]

NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781

G

cytochrome c oxidase subunit 6A1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of COX6A1 mRNA

NCBI chr12:41,261,983...41,265,037
Ensembl chr12:41,261,967...41,265,041

G

cytochrome c oxidase subunit 6B1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA]

NCBI chr 1:85,875,080...85,884,081
Ensembl chr 1:85,875,109...85,884,001
Ensembl chr 2:85,875,109...85,884,001

G

cytochrome c oxidase subunit 7A1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of COX7A1 mRNA

NCBI chr 1:85,422,162...85,447,530
Ensembl chr 1:85,441,871...85,445,151

G

cytochrome c oxidase subunit 7A2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of COX7A2 mRNA

NCBI chr 8:80,716,824...80,720,922
Ensembl chr14:51,301,168...51,301,633
Ensembl chr 8:51,301,168...51,301,633

G

cytochrome c oxidase subunit 7A2 like

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of COX7A2L mRNA

NCBI chr 6:11,184,064...11,198,287
Ensembl chr 6:11,184,285...11,198,273

G

complexin 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of CPLX1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of CPLX1 protein

NCBI chr14:1,184,677...1,216,392

G

copine 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CPNE4 mRNA

NCBI chr 8:105,177,376...105,653,075
Ensembl chr 8:105,177,376...105,653,068

G

copine 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CPNE5 mRNA

NCBI chr20:7,206,742...7,289,309
Ensembl chr20:7,206,742...7,288,883

G

copine 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CPNE6 mRNA

NCBI chr15:28,998,293...29,005,044
Ensembl chr15:28,998,293...29,005,044

G

copine 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CPNE7 mRNA

NCBI chr19:51,164,316...51,182,676
Ensembl chr19:51,166,034...51,182,677

G

cAMP responsive element binding protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA]
[Paraquat co-treated with Maneb] results in decreased expression of and results in decreased phosphorylation of CREB1 protein; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 protein; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 protein modified form; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of and results in decreased phosphorylation of CREB1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of CREB1 mRNA]

PMID:23963992 PMID:27460631 PMID:33368748

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

cysteine-rich protein 2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of CRIP2 mRNA

NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065

G

cytokine receptor-like factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CRLF1 mRNA

NCBI chr16:18,924,722...18,936,049
Ensembl chr16:18,924,722...18,935,997

G

cytokine receptor-like factor 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CRLF2 mRNA; [Paraquat co-treated with Maneb] affects the expression of CRLF2 mRNA

PMID:22563483 PMID:36117858

NCBI chr14:103,943...108,643
Ensembl chr14:103,939...108,642

G

carnitine O-octanoyltransferase

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of CROT mRNA

NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109

G

colony stimulating factor 1 receptor

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of CSF1R mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CSF1R mRNA]

NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415

G

colony stimulating factor 2 receptor subunit alpha

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of CSF2RA mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CSF2RA mRNA]

NCBI chr14:98,089...103,261
Ensembl chr14:89,172...103,128

G

cathepsin L

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of CTSL mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CTSL mRNA]

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cortactin binding protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CTTNBP2 mRNA

NCBI chr 4:46,800,975...46,964,681
Ensembl chr 4:46,800,981...46,964,631

G

cullin 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of CUL5 mRNA

NCBI chr 8:54,012,963...54,066,751
Ensembl chr 8:54,016,006...54,066,666

G

cytochrome b-245 beta chain

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of CYBB mRNA; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB mRNA]; diphenyleneiodonium inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB mRNA]
[Maneb co-treated with Paraquat] results in increased expression of CYBB protein; [Paraquat co-treated with Maneb] results in increased expression of CYBB protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CYBB protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein]

PMID:29568078 PMID:30797899 PMID:32375810 PMID:34052309

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome c-1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of CYC1 mRNA

NCBI chr 7:108,067,106...108,069,483
Ensembl chr 7:108,067,115...108,069,479

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases activity
decreases expression
increases expression

Maneb results in increased activity of CYP1A1 protein
Maneb results in decreased expression of CYP1A1 mRNA
Maneb results in increased expression of CYP1A1 mRNA; Maneb results in increased expression of CYP1A1 protein

PMID:20888808 PMID:32194361

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein; [Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein]; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases expression

Maneb results in decreased expression of CYP2C19 protein

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions
decreases expression

Ketoconazole inhibits the reaction [Maneb results in decreased expression of CYP2D22 protein]

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity
increases expression
multiple interactions
increases activity

Maneb results in decreased activity of CYP2E1 protein
Maneb results in increased expression of CYP2E1 mRNA; Maneb results in increased expression of CYP2E1 protein
[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein; [Maneb co-treated with Paraquat] results in increased expression of CYP2E1 mRNA; Acetylcysteine inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein]; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of and results in increased activity of CYP2E1 protein]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of CYP2E1 mRNA]; Maneb results in increased expression of and results in increased activity of CYP2E1 protein; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of and results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [Maneb results in increased expression of CYP2E1 mRNA]
Maneb results in increased activity of CYP2E1 protein
[Maneb co-treated with Paraquat] results in increased expression of CYP2E1 mRNA; [Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein; [Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]

PMID:11043497 PMID:16510128 PMID:20888808 PMID:20964710 PMID:23159886

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

Maneb results in decreased expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

DAB adaptor protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DAB1 mRNA

NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552

G

dishevelled-binding antagonist of beta-catenin 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DACT3 mRNA

NCBI chr 1:77,546,900...77,558,631
Ensembl chr 1:77,546,900...77,558,630

G

death associated protein 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA]

NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461

G

diazepam binding inhibitor

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of DBI mRNA

NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693

G

drebrin 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of DBN1 mRNA

NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984

G

DDB1 and CUL4 associated factor 12-like 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DCAF12L1 mRNA

NCBI chr X:123,695,286...123,698,905
Ensembl chr X:123,695,286...123,698,905

G

DDB1 and CUL4 associated factor 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DCAF5 mRNA

NCBI chr 6:99,171,506...99,260,183
Ensembl chr 6:99,171,506...99,260,110

G

DDB1 and CUL4 associated factor 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DCAF6 mRNA

NCBI chr13:77,626,257...77,727,645
Ensembl chr13:77,626,307...77,727,512

G

DNA cross-link repair 1B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DCLRE1B mRNA

NCBI chr 2:191,309,909...191,318,399
Ensembl chr 2:191,309,913...191,318,423

G

dimethylarginine dimethylaminohydrolase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DDAH1 mRNA

NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339

G

DNA-damage-inducible transcript 4

increases expression

Maneb results in increased expression of DDIT4 protein

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

DEAD-box helicase 20

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DDX20 mRNA

NCBI chr 2:193,158,761...193,168,484
Ensembl chr 2:193,158,823...193,166,774

G

DEAD-box helicase 25

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DDX25 mRNA

NCBI chr 8:33,894,224...33,910,377
Ensembl chr 8:33,894,232...33,921,764

G

DEAD-box helicase 5

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of DDX5 mRNA

NCBI chr10:91,723,508...91,732,210
Ensembl chr10:91,723,508...91,732,283

G

DENN domain containing 6B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DENND6B mRNA

NCBI chr 7:120,261,679...120,273,667
Ensembl chr 7:120,261,679...120,273,494

G

DEP domain containing 5, GATOR1 subcomplex subunit

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DEPDC5 mRNA

NCBI chr14:77,732,297...77,862,924
Ensembl chr14:77,732,297...77,862,794

G

desumoylating isopeptidase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DESI1 mRNA

NCBI chr 7:113,519,974...113,542,834
Ensembl chr 7:113,519,980...113,542,845

G

diacylglycerol kinase epsilon

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DGKE mRNA

NCBI chr10:73,853,030...73,877,334
Ensembl chr10:73,855,583...73,877,100

G

diacylglycerol kinase, gamma

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DGKG mRNA

NCBI chr11:78,384,212...78,579,158
Ensembl chr11:78,384,458...78,577,212

G

diacylglycerol kinase, iota

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of DGKI mRNA

NCBI chr 4:65,410,878...65,872,733
Ensembl chr 4:65,420,108...65,872,733

G

diacylglycerol kinase, theta

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DGKQ mRNA

NCBI chr14:1,059,125...1,073,131
Ensembl chr14:1,059,170...1,073,131

G

DExH-box helicase 34

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DHX34 mRNA

NCBI chr 1:76,880,867...76,905,148
Ensembl chr 1:76,880,867...76,905,113

G

iodothyronine deiodinase 1

decreases activity

Maneb results in decreased activity of DIO1 protein

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

disco-interacting protein 2 homolog B

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of DIP2B mRNA

NCBI chr 7:131,174,575...131,350,417
Ensembl chr 7:131,174,567...131,349,092

G

DISC1 scaffold protein

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DISC1 mRNA

NCBI chr19:53,014,201...53,223,617
Ensembl chr19:53,014,616...53,219,778

G

discs large MAGUK scaffold protein 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of DLG3 mRNA

NCBI chr X:65,859,653...65,911,887
Ensembl chr X:65,860,172...65,910,322

G

delta like canonical Notch ligand 1

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DLL1 mRNA

NCBI chr 1:56,312,062...56,320,177
Ensembl chr 1:56,312,066...56,320,179

G

dihydrolipoamide S-succinyltransferase

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of DLST protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DLST protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DLST protein]

NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296

G

DMRT-like family A2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of DMRTA2 mRNA

NCBI chr 5:124,805,883...124,811,694
Ensembl chr 5:124,805,883...124,811,630

G

DnaJ heat shock protein family (Hsp40) member B6

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of DNAJB6 mRNA

NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659

G

dynamin 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA]

NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157

G

dedicator of cytokinesis 10

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DOCK10 mRNA

NCBI chr 9:81,843,599...82,101,540
Ensembl chr 9:81,843,604...82,101,525

G

docking protein 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DOK7 mRNA

NCBI chr14:75,665,444...75,699,413
Ensembl chr14:75,666,744...75,699,386

G

diphthamine biosynthesis 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DPH6 mRNA

NCBI chr 3:101,307,229...101,437,463
Ensembl chr 3:101,307,231...101,534,603

G

dpy-19 like C-mannosyltransferase 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DPY19L3 mRNA

NCBI chr 1:88,350,303...88,417,339
Ensembl chr 1:88,350,303...88,417,339

G

dihydropyrimidine dehydrogenase

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of DPYD mRNA

NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982

G

dopamine receptor D2

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD2 mRNA

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D4

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of DRD4 protein

NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553

G

dopamine receptor D5

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA

NCBI chr14:72,487,950...72,491,050
Ensembl chr14:72,489,347...72,490,774

G

dystrophin related protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DRP2 mRNA

NCBI chr X:97,607,577...97,658,117
Ensembl chr X:97,607,719...97,655,684

G

dual specificity phosphatase 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

deoxyuridine triphosphatase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DUT mRNA; [Maneb co-treated with Paraquat] results in increased expression of DUT mRNA

NCBI chr 3:112,498,864...112,509,994
Ensembl chr 3:112,498,982...112,510,771

G

dynein cytoplasmic 1 intermediate chain 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DYNC1I1 mRNA

NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149

G

dynein cytoplasmic 2 light intermediate chain 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of DYNC2LI1 mRNA

NCBI chr 6:9,992,537...10,025,355
Ensembl chr 6:9,992,541...10,025,336

G

dual specificity tyrosine phosphorylation regulated kinase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of DYRK2 mRNA

NCBI chr 7:54,348,724...54,381,363
Ensembl chr 7:54,349,610...54,380,106

G

E2F transcription factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA]

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

extracellular matrix protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ECM2 mRNA

NCBI chr17:15,120,194...15,152,536
Ensembl chr17:15,120,196...15,152,516

G

eukaryotic translation elongation factor 1 alpha 1

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of EEF1A1 mRNA

NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839

G

eukaryotic translation elongation factor 1 gamma

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA]

NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382

G

ephrin A3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EFNA3 mRNA

NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736

G

ephrin B1

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of EFNB1 mRNA

NCBI chr X:64,257,351...64,270,158
Ensembl chr X:64,257,351...64,270,157

G

ephrin B3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EFNB3 mRNA

NCBI chr10:54,274,506...54,281,951
Ensembl chr10:54,274,506...54,280,471

G

EFR3 homolog B

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of EFR3B mRNA

NCBI chr 6:26,947,436...27,021,113
Ensembl chr 6:26,948,540...27,020,933

G

EGF-like-domain, multiple 8

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EGFL8 mRNA

NCBI chr20:4,132,930...4,136,024
Ensembl chr20:4,133,629...4,136,018

G

early growth response 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 4

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of EGR4 mRNA

NCBI chr 4:118,047,869...118,050,328
Ensembl chr 4:118,047,869...118,050,328

G

EP300 interacting inhibitor of differentiation 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EID2 mRNA

NCBI chr 1:83,538,274...83,539,599

G

eukaryotic translation initiation factor 2 alpha kinase 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EIF2AK4 mRNA

NCBI chr 3:105,356,261...105,441,630
Ensembl chr 3:105,356,261...105,441,630

G

eukaryotic translation initiation factor 4, gamma 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA]

NCBI chr 1:165,181,433...165,193,583
Ensembl chr 1:165,181,434...165,193,588

G

ELAV like RNA binding protein 4

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ELAVL4 mRNA

NCBI chr 5:125,056,848...125,200,543
Ensembl chr 5:125,056,848...125,200,446

G

extracellular leucine-rich repeat and fibronectin type III domain containing 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ELFN2 mRNA

NCBI chr 7:110,220,293...110,272,770
Ensembl chr 7:110,225,919...110,272,433

G

ETS transcription factor ELK1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA]

NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713

G

elongation factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ELOF1 mRNA

NCBI chr 8:20,645,336...20,650,888
Ensembl chr 8:20,645,336...20,650,579

G

ELOVL fatty acid elongase 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ELOVL6 mRNA

NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186

G

embigin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EMB mRNA

NCBI chr 2:49,070,509...49,125,042
Ensembl chr 2:49,069,087...49,125,050

G

Emx2 opposite strand/antisense RNA

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EMX2OS mRNA

NCBI chr 1:258,569,637...258,626,810

G

endonuclease, poly(U)-specific

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ENDOU mRNA

NCBI chr 7:128,844,872...128,866,572
Ensembl chr 7:128,844,862...128,866,596

G

enolase 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ENO1 protein; [Paraquat co-treated with Maneb] results in decreased expression of ENO1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of ENO1 protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ENO1 protein]

PMID:17532186 PMID:18386188 PMID:23562983

NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336

G

enolase 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ENO2 protein

NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980

G

ectonucleotide pyrophosphatase/phosphodiesterase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ENPP1 mRNA

NCBI chr 1:20,698,746...20,763,741
Ensembl chr 1:20,698,764...20,763,715

G

erythrocyte membrane protein band 4.1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EPB41 mRNA

NCBI chr 5:144,110,010...144,264,037
Ensembl chr 5:144,111,906...144,237,821

G

erythrocyte membrane protein band 4.1 like 4B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EPB41L4B mRNA

NCBI chr 5:71,691,706...71,852,583
Ensembl chr 5:71,694,331...71,851,990

G

Eph receptor B6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EPHB6 mRNA

NCBI chr 4:70,491,973...70,507,230
Ensembl chr 4:70,491,973...70,507,230

G

EPM2A glucan phosphatase, laforin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EPM2A mRNA; [Maneb co-treated with Paraquat] results in increased expression of EPM2A mRNA

NCBI chr 1:5,727,111...5,845,338
Ensembl chr 1:5,727,066...5,920,555

G

EPM2A interacting protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EPM2AIP1 mRNA

NCBI chr 8:111,233,871...111,241,219
Ensembl chr 8:111,233,826...111,241,871

G

ERCC excision repair 2, TFIIH core complex helicase subunit

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ERCC2 mRNA

NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102

G

ERCC excision repair 6 like 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ERCC6L2 mRNA

NCBI chr17:1,076,486...1,311,281
Ensembl chr17:1,216,428...1,310,275

G

ERBB receptor feedback inhibitor 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ERRFI1 mRNA

NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282

G

enhancer trap locus 4

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of ETL4 mRNA

NCBI chr17:82,841,075...83,304,868
Ensembl chr17:82,495,041...83,304,715

G

exosome component 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EXOSC2 mRNA; [Maneb co-treated with Paraquat] results in increased expression of EXOSC2 mRNA

NCBI chr 3:14,962,930...14,973,645
Ensembl chr 3:14,962,917...14,973,575

G

exostosin glycosyltransferase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EXT1 mRNA

NCBI chr 7:84,375,769...84,654,625
Ensembl chr 7:84,375,784...84,655,357

G

EYA transcriptional coactivator and phosphatase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of EYA1 mRNA

NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483

G

fatty acid amide hydrolase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FAAH mRNA

NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677

G

fatty acid binding protein 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FABP3 mRNA

NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718

G

family with sequence similarity 118, member B

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FAM118B mRNA

NCBI chr 8:33,566,681...33,617,310
Ensembl chr 8:33,566,669...33,617,270

G

family with sequence similarity 171, member A2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FAM171A2 mRNA

NCBI chr10:87,393,888...87,404,051
Ensembl chr10:87,394,007...87,404,053

G

family with sequence similarity 241 member B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FAM241B mRNA

NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084

G

family with sequence similarity 72, member A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FAM72A mRNA

NCBI chr13:42,967,701...42,979,083
Ensembl chr13:42,967,578...42,984,208

G

Fas cell surface death receptor

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

FAT atypical cadherin 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FAT4 mRNA

NCBI chr 2:121,927,266...122,056,700
Ensembl chr 2:121,927,942...122,056,707

G

F-box protein 27

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FBXO27 mRNA

NCBI chr 1:83,965,426...83,987,781
Ensembl chr 1:83,965,986...83,987,778

G

F-box protein 41

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FBXO41 mRNA

NCBI chr 4:118,007,517...118,039,547
Ensembl chr 4:118,010,978...118,039,406

G

farnesyl diphosphate farnesyl transferase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

fasciculation and elongation protein zeta 1

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of FEZ1 mRNA

NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683

G

fibroblast growth factor receptor 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FGFR3 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FGFR3 mRNA]

NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341

G

FHF complex subunit HOOK interacting protein 2B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FHIP2B mRNA

NCBI chr15:45,656,641...45,674,603
Ensembl chr15:45,656,647...45,674,105

G

four and a half LIM domains 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FHL2 mRNA

NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192

G

FKBP prolyl isomerase 4

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of FKBP4 mRNA

NCBI chr 4:161,703,379...161,711,833
Ensembl chr 4:161,703,379...161,711,833

G

FKBP prolyl isomerase 5

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of FKBP5 mRNA

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

fibronectin leucine rich transmembrane protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FLRT1 mRNA

NCBI chr 1:204,275,785...204,292,844
Ensembl chr 1:204,275,367...204,353,750

G

fibronectin leucine rich transmembrane protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FLRT2 mRNA

NCBI chr 6:114,777,547...114,872,688
Ensembl chr 6:114,777,599...114,872,785

G

FLYWCH family member 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FLYWCH2 mRNA

NCBI chr10:12,798,757...12,807,082
Ensembl chr10:12,798,762...12,806,439

G

fibronectin type III domain containing 5

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FNDC5 mRNA

NCBI chr 5:141,481,593...141,491,257
Ensembl chr 5:141,481,590...141,490,731

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FOS mRNA; [Maneb co-treated with Paraquat] results in increased expression of FOS mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FOS mRNA]
[Paraquat co-treated with Maneb] results in decreased expression of FOS mRNA; [Paraquat co-treated with Maneb] results in decreased expression of FOS protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of FOS mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of FOS protein]

PMID:23963992 PMID:27460631 PMID:33368748 PMID:36117858

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box K1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FOXK1 mRNA

NCBI chr12:12,110,119...12,175,089
Ensembl chr12:12,115,950...12,175,089

G

FAD-dependent oxidoreductase domain containing 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FOXRED2 mRNA

NCBI chr 7:109,521,761...109,538,300
Ensembl chr 7:109,521,761...109,540,874

G

FRAT regulator of WNT signaling pathway 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FRAT1 mRNA

NCBI chr 1:240,638,309...240,640,857
Ensembl chr 1:240,638,296...240,640,945

G

ferric-chelate reductase 1-like

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of FRRS1L mRNA

NCBI chr 5:71,655,911...71,690,132
Ensembl chr 5:71,659,284...71,690,108

G

FTX transcript, XIST regulator

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FTX mRNA

NCBI chr X:68,588,349...68,630,338

G

FXYD domain-containing ion transport regulator 6

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of FXYD6 mRNA

NCBI chr 8:45,679,054...45,705,958
Ensembl chr 8:45,678,885...45,705,958

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

Maneb results in decreased expression of G6PC1 mRNA

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glucose-6-phosphate dehydrogenase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of G6PDX mRNA

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

gamma-aminobutyric acid type A receptor subunit alpha 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GABRA2 mRNA

NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,097,279...37,228,944

G

gamma-aminobutyric acid type A receptor subunit alpha6

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of GABRA6 mRNA

NCBI chr10:26,810,411...26,825,768
Ensembl chr10:26,810,423...26,825,769

G

gamma-aminobutyric acid type A receptor subunit gamma 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GABRG1 mRNA

NCBI chr14:37,396,217...37,469,606
Ensembl chr14:37,396,294...37,635,956

G

cyclin G associated kinase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GAK mRNA

NCBI chr14:1,089,853...1,164,098
Ensembl chr14:1,089,866...1,216,398

G

polypeptide N-acetylgalactosaminyltransferase 4

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of GALNT4 mRNA

NCBI chr 7:33,925,229...33,927,770

G

gigaxonin

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of GAN mRNA

NCBI chr19:45,207,783...45,265,066
Ensembl chr19:45,207,184...45,254,107

G

growth arrest specific 5

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of GAS5 mRNA

NCBI chr13:73,303,611...73,306,932

G

growth arrest specific 6

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of GAS6 mRNA

NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904

G

glutamate-cysteine ligase, catalytic subunit

increases expression
increases activity

[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of GCLC mRNA
Maneb results in increased activity of GCLC protein

PMID:15527874 PMID:21402726

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

guanine deaminase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GDA mRNA

NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416

G

ganglioside-induced differentiation-associated protein 1-like 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GDAP1L1 mRNA

NCBI chr 3:152,110,225...152,129,693
Ensembl chr 3:152,110,253...152,128,711

G

growth differentiation factor 11

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GDF11 mRNA

NCBI chr 7:1,311,732...1,325,211
Ensembl chr 7:1,311,732...1,320,725

G

glial fibrillary acidic protein

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of GFAP protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of GFAP protein]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

GDNF family receptor alpha 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of GFRA2 mRNA

NCBI chr15:45,941,841...46,033,715
Ensembl chr15:45,941,828...46,033,714

G

GDNF family receptor alpha 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GFRA4 mRNA

NCBI chr 3:118,254,937...118,262,252
Ensembl chr 3:118,255,402...118,258,329

G

growth hormone 1

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of GH mRNA

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

gastrokine 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of GKN3 mRNA

NCBI chr 4:119,828,859...119,833,924
Ensembl chr 4:119,829,005...119,834,842

G

glucuronic acid epimerase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GLCE mRNA

NCBI chr 8:62,546,104...62,612,144
Ensembl chr 8:62,546,107...62,612,040

G

ganglioside GM2 activator

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of GM2A mRNA

NCBI chr10:39,219,221...39,231,756
Ensembl chr10:39,219,243...39,231,757

G

glia maturation factor, beta

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of GMFB mRNA; [Paraquat co-treated with Maneb] results in decreased expression of GMFB protein

NCBI chr15:20,069,923...20,081,005
Ensembl chr15:20,067,263...20,080,331

G

G protein subunit alpha i1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GNAI1 mRNA

NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417

G

G protein subunit alpha L

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GNAL mRNA

NCBI chr18:60,622,311...60,762,599
Ensembl chr18:60,622,311...60,762,599

G

G protein subunit beta 5

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of GNB5 mRNA

NCBI chr 8:76,076,120...76,105,069
Ensembl chr 8:76,073,306...76,105,069

G

G protein subunit gamma 13

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GNG13 mRNA

NCBI chr10:14,741,179...14,743,083
Ensembl chr10:14,741,239...14,743,083

G

G protein subunit gamma 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GNG3 mRNA

NCBI chr 1:205,731,837...205,733,603
Ensembl chr 1:205,731,837...205,733,603

G

G protein subunit gamma 5

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of GNG5 mRNA

NCBI chr 2:235,394,680...235,403,177
Ensembl chr 1:77,292,043...77,292,513

G

G protein subunit gamma transducin 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of GNGT2 mRNA

NCBI chr10:80,776,003...80,784,235

G

golgi associated PDZ and coiled-coil motif containing

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GOPC mRNA

NCBI chr20:31,727,617...31,776,904
Ensembl chr20:31,727,620...31,776,903

G

glycerophosphocholine phosphodiesterase 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of GPCPD1 mRNA

NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517

G

G protein-coupled receptor 22

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GPR22 mRNA

NCBI chr 6:48,309,619...48,317,864
Ensembl chr 6:48,310,505...48,317,486

G

G protein-coupled receptor 27

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of GPR27 mRNA

NCBI chr 4:132,328,364...132,329,497
Ensembl chr 4:132,328,364...132,329,497

G

G protein-coupled receptor associated sorting protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GPRASP1 mRNA

NCBI chr X:98,764,853...98,772,685
Ensembl chr X:98,709,841...98,772,851

G

G protein-coupled receptor associated sorting protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GPRASP2 mRNA

NCBI chr X:98,817,668...98,823,814
Ensembl chr X:98,817,593...98,824,402

G

glutathione peroxidase 1

decreases expression
decreases activity
multiple interactions

Maneb results in decreased expression of GPX1 mRNA
Maneb results in decreased activity of GPX1 protein
[Maneb co-treated with Paraquat] results in increased expression of GPX1 mRNA

PMID:26210702 PMID:28322069 PMID:29859004

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 4

increases expression
multiple interactions

Maneb results in increased expression of GPX4 mRNA
[Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein
[Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein]; NFE2L2 gene mutant form inhibits the reaction [Maneb results in increased expression of GPX4 mRNA]

PMID:23764462 PMID:30797899

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

growth factor receptor bound protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]

NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309

G

glutamate ionotropic receptor delta type subunit 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GRID1 mRNA

NCBI chr16:10,138,564...10,885,803
Ensembl chr16:10,138,925...10,885,808

G

glutamate ionotropic receptor kainate type subunit 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GRIK2 mRNA

NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375

G

G protein-coupled receptor kinase 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GRK6 mRNA

NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,177,019...9,192,644

G

gasdermin E

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GSDME mRNA

NCBI chr 4:79,258,799...79,321,129
Ensembl chr 4:79,257,804...79,320,806

G

glycogen synthase kinase 3 beta

multiple interactions

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

G1 to S phase transition 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GSPT2 mRNA

NCBI chr X:59,587,237...59,589,758
Ensembl chr X:59,587,276...59,594,162

G

glutathione-disulfide reductase

multiple interactions

[Acetylcysteine co-treated with Paraquat co-treated with Maneb] results in increased activity of GSR protein; [Silymarin co-treated with Maneb] results in increased activity of GSR protein; [Silymarin co-treated with Paraquat co-treated with Maneb] results in increased activity of GSR protein
[NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of GSR protein

PMID:23159886 PMID:23764462

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase alpha 3

increases expression

Maneb results in increased expression of GSTA3 mRNA

NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240

G

glutathione S-transferase alpha 4

multiple interactions
increases activity
increases expression

[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein; [Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA; Acetylcysteine promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein]; Acetylcysteine promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA]; Acetylcysteine promotes the reaction [Maneb results in increased expression of and results in increased activity of GSTA4 protein]; Acetylcysteine promotes the reaction [Maneb results in increased expression of GSTA4 mRNA]; Maneb results in increased expression of and results in increased activity of GSTA4 protein; Silymarin promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein]; Silymarin promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA]; Silymarin promotes the reaction [Maneb results in increased expression of and results in increased activity of GSTA4 protein]; Silymarin promotes the reaction [Maneb results in increased expression of GSTA4 mRNA]
Maneb results in increased activity of GSTA4 protein
Maneb results in increased expression of GSTA4 mRNA; Maneb results in increased expression of GSTA4 protein

PMID:20888808 PMID:23159886

NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182

G

glutathione S-transferase pi 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA]

PMID:23963992 PMID:36117858

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

guanylate cyclase 1 soluble subunit alpha 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of GUCY1A2 mRNA

NCBI chr 8:500,212...900,201
Ensembl chr 8:500,212...889,203

G

guanylate kinase 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of GUK1 mRNA

NCBI chr10:43,971,514...43,988,658
Ensembl chr10:43,971,509...43,980,107

G

H2A clustered histone 20

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of H2AC20 mRNA

NCBI chr 2:183,779,879...183,780,357

G

H2A.X variant histone

multiple interactions

[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

H2B clustered histone 9

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of H2BC9 mRNA

NCBI chr17:42,470,593...42,478,590

G

hyaluronan binding protein 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HABP4 mRNA

NCBI chr17:934,931...957,604
Ensembl chr17:935,654...957,565

G

hyaluronan and proteoglycan link protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HAPLN1 mRNA

NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777

G

hemoglobin alpha, adult chain 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HBA-A1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of HBA-A1 mRNA

PMID:18386188 PMID:36117858

NCBI chr10:15,337,265...15,338,121
Ensembl chr10:15,307,815...15,338,392

G

hemoglobin alpha, adult chain 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HBA-A2 mRNA

NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392

G

histone deacetylase 3

decreases activity

Maneb results in decreased activity of HDAC3 protein

NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856

G

histone deacetylase 6

decreases activity
multiple interactions

Maneb results in decreased activity of HDAC6 protein
[Maneb co-treated with Paraquat] results in decreased expression of HDAC6 mRNA

PMID:21251949 PMID:36117858

NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441

G

helicase, POLQ-like

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HELQ mRNA

NCBI chr14:8,818,582...8,862,926
Ensembl chr14:8,818,592...8,862,960

G

HECT and RLD domain containing E3 ubiquitin protein ligase 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HERC3 mRNA

NCBI chr 4:87,952,202...88,042,492
Ensembl chr 4:87,952,274...88,042,488

G

hes family bHLH transcription factor 3

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of HES3 mRNA

NCBI chr 5:162,793,611...162,799,578
Ensembl chr 5:162,794,367...162,796,261

G

hes-related family bHLH transcription factor with YRPW motif 2

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA; [Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA

PMID:23017109 PMID:36117858

NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218

G

hes-related family bHLH transcription factor with YRPW motif-like

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEYL mRNA

NCBI chr 5:135,508,160...135,525,152
Ensembl chr 5:135,508,160...135,525,152

G

HIVEP zinc finger 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HIVEP2 mRNA

NCBI chr 1:8,358,205...8,555,993
Ensembl chr 1:8,359,289...8,555,993

G

hexokinase 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of HK1 mRNA

NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131

G

HLF transcription factor, PAR bZIP family member

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of HLF mRNA

NCBI chr10:75,154,244...75,211,884
Ensembl chr10:75,154,507...75,211,935

G

high mobility group AT-hook 2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of HMGA2 mRNA

NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784

G

high mobility group nucleosome binding domain 5

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of HMGN5 mRNA

NCBI chr X:74,085,871...74,094,488
Ensembl chr X:74,085,875...74,094,441

G

HMG-box containing 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HMGXB3 mRNA; [Maneb co-treated with Paraquat] results in increased expression of HMGXB3 mRNA

NCBI chr18:54,590,558...54,638,050
Ensembl chr18:54,590,560...54,638,155

G

heme oxygenase 1

increases expression
multiple interactions

Maneb results in increased expression of HMOX1 protein
[NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of HMOX1 protein

PMID:15527874 PMID:23764462

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

histamine N-methyltransferase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HNMT mRNA

NCBI chr 3:6,591,804...6,623,821
Ensembl chr 3:6,591,463...6,624,012

G

heterogeneous nuclear ribonucleoprotein K

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of HNRNPK mRNA

NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997

G

homer scaffold protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HOMER1 mRNA

NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785

G

homer scaffold protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of HOMER2 mRNA

NCBI chr 1:135,558,977...135,659,780
Ensembl chr 1:135,567,414...135,659,772

G

hook microtubule-tethering protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HOOK1 mRNA

NCBI chr 5:110,824,501...110,887,791
Ensembl chr 5:110,824,501...110,887,787

G

hippocalcin-like 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HPCAL1 mRNA

NCBI chr 6:40,478,206...40,584,721
Ensembl chr 6:40,478,208...40,584,687

G

hippocalcin-like 4

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of HPCAL4 mRNA

NCBI chr 5:135,454,477...135,466,417
Ensembl chr 5:135,454,540...135,466,416

G

harakiri, BCL2 interacting protein

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HRK mRNA

NCBI chr12:38,387,484...38,409,652

G

hydroxysteroid 11-beta dehydrogenase 2

decreases activity

Maneb results in decreased activity of HSD11B2 protein

NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899

G

heat shock transcription factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA]

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

heat shock protein 90 alpha family class A member 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA; [Paraquat co-treated with Maneb] results in increased expression of HSP90AA1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA]

PMID:18386188 PMID:23963992

NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein family A (Hsp70) member 1B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HSPA1B mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSPA1B mRNA]

NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240

G

heat shock protein family A (Hsp70) member 5

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of HSPA5 mRNA

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

5-hydroxytryptamine receptor 2C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HTR2C mRNA

NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287

G

HUS1 checkpoint clamp component

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of HUS1 mRNA

NCBI chr14:83,688,702...83,703,466
Ensembl chr14:83,688,708...83,703,442

G

intercellular adhesion molecule 1

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of ICAM1 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ICAM1 mRNA]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

intercellular adhesion molecule 2

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of ICAM2 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ICAM2 mRNA]

NCBI chr10:91,308,608...91,319,536
Ensembl chr10:91,308,538...91,315,293

G

isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein]

NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084

G

iduronate 2-sulfatase

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of IDS mRNA

NCBI chr X:149,025,976...149,046,641
Ensembl chr X:149,025,976...149,046,663

G

immediate early response 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of IER3 mRNA

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

immediate early response 5-like

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of IER5L mRNA

NCBI chr 3:13,744,056...13,745,647
Ensembl chr 3:13,744,078...13,745,647

G

interferon, alpha-inducible protein 27 like 2A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of IFI27L2A mRNA

NCBI chr 6:122,598,872...122,600,358
Ensembl chr 6:122,598,872...122,600,360

G

interferon gamma

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA]

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

immunoglobin superfamily, member 21

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of IGSF21 mRNA

NCBI chr 5:152,287,834...152,512,174
Ensembl chr 5:152,287,835...152,512,174

G

immunoglobulin superfamily, member 5

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of IGSF5 mRNA

NCBI chr11:35,686,513...35,729,396
Ensembl chr11:35,686,705...35,741,129

G

interleukin 1 beta

multiple interactions
increases expression

[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of IL1B mRNA]
[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA; [Maneb co-treated with Paraquat] results in increased expression of IL1B protein; [Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA; [Paraquat co-treated with Maneb] results in increased expression of IL1B protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]

PMID:23159886 PMID:23963992 PMID:29568078 PMID:32169474 PMID:32375810 More...

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of IL6 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit beta A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of INHBA mRNA; [Paraquat co-treated with Maneb] affects the expression of INHBA mRNA

PMID:22563483 PMID:23017109

NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982

G

inka box actin regulator 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of FAM212B mRNA

NCBI chr 2:193,185,275...193,200,643
Ensembl chr 2:193,185,275...193,200,642

G

inositol polyphosphate-4-phosphatase type I A

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of INPP4A mRNA

NCBI chr 9:39,528,245...39,650,574
Ensembl chr 9:39,528,674...39,646,581

G

inositol polyphosphate-4-phosphatase type II B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of INPP4B mRNA

NCBI chr19:25,920,189...26,670,085
Ensembl chr19:25,925,358...26,280,634

G

inositol polyphosphate-5-phosphatase D

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of INPP5D mRNA

NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746

G

insulin induced gene 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of INSIG1 mRNA

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

IQ motif and Sec7 domain ArfGEF 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of IQSEC3 mRNA

NCBI chr 4:154,610,933...154,707,310
Ensembl chr 4:154,610,934...154,707,310

G

insulin receptor substrate 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of IRS2 mRNA; [Maneb co-treated with Paraquat] results in increased expression of IRS2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IRS2 mRNA]

PMID:23963992 PMID:36117858

NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482

G

immunoglobulin superfamily containing leucine-rich repeat 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ISLR2 mRNA

NCBI chr 8:58,608,165...58,616,246
Ensembl chr 8:58,608,709...58,614,650

G

integrin subunit alpha 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ITGA7 mRNA

NCBI chr 7:1,360,125...1,388,886
Ensembl chr 7:1,359,940...1,388,450

G

integrin subunit alpha M

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ITGAM protein; [Paraquat co-treated with Maneb] results in increased expression of ITGAM mRNA; [Paraquat co-treated with Maneb] results in increased expression of ITGAM protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ITGAM protein]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ITGAM protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ITGAM mRNA]

PMID:28202386 PMID:30797899 PMID:32169474 PMID:32375810

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

integrin subunit beta 8

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of ITGB8 mRNA

NCBI chr 6:140,125,002...140,208,261
Ensembl chr 6:140,127,203...140,208,476

G

inositol 1,4,5-trisphosphate receptor, type 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ITPR1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ITPR1 mRNA]

NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491

G

influenza virus NS1A binding protein

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of IVNS1ABP mRNA

NCBI chr13:63,427,040...63,446,701
Ensembl chr13:63,427,041...63,446,701

G

Jupiter microtubule associated homolog 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of JPT1 mRNA

NCBI chr10:100,744,468...100,762,504
Ensembl chr10:100,686,797...100,784,513

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of JUN mRNA; [Paraquat co-treated with Maneb] results in decreased expression of JUN protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of JUN mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of JUN protein]

PMID:27460631 PMID:33368748

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

potassium voltage-gated channel subfamily A member 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of KCNA2 mRNA

NCBI chr 2:194,704,555...194,718,387
Ensembl chr 2:194,704,639...194,718,400

G

potassium voltage-gated channel subfamily A member 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCNA5 mRNA

NCBI chr 4:159,354,689...159,358,173
Ensembl chr 4:159,350,097...159,357,697

G

potassium voltage-gated channel subfamily C member 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCNC1 mRNA

NCBI chr 1:96,902,953...96,944,744
Ensembl chr 1:96,902,953...96,944,744

G

potassium voltage-gated channel subfamily C member 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCNC3 mRNA

NCBI chr 1:95,080,960...95,095,165
Ensembl chr 1:95,080,960...95,095,160

G

potassium voltage-gated channel subfamily D member 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCND1 mRNA

NCBI chr X:14,661,688...14,678,745
Ensembl chr X:14,662,357...14,677,233

G

potassium voltage-gated channel subfamily D member 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCND3 mRNA

NCBI chr 2:192,937,950...193,155,345
Ensembl chr 2:192,937,950...193,155,345

G

potassium voltage-gated channel subfamily H member 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of KCNH3 mRNA

NCBI chr 7:130,365,593...130,383,859
Ensembl chr 7:130,366,011...130,383,855

G

potassium inwardly-rectifying channel, subfamily J, member 12

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCNJ12 mRNA

NCBI chr10:45,696,621...45,745,528
Ensembl chr10:45,696,849...45,745,492

G

potassium inwardly-rectifying channel, subfamily J, member 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of KCNJ3 mRNA

NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124

G

potassium two pore domain channel subfamily K member 12

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCNK12 mRNA

NCBI chr 6:6,740,147...6,790,664
Ensembl chr 6:6,739,991...6,790,661

G

potassium calcium-activated channel subfamily M alpha 1

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of KCNMA1 mRNA

NCBI chr15:302,480...1,007,675
Ensembl chr15:302,214...1,001,198

G

potassium calcium-activated channel subfamily M regulatory beta subunit 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCNMB4 mRNA

NCBI chr 7:52,066,145...52,119,098
Ensembl chr 7:52,066,136...52,119,278

G

potassium channel tetramerization domain containing 10

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KCTD10 mRNA

NCBI chr12:42,230,159...42,248,792
Ensembl chr12:42,230,269...42,248,783

G

KH RNA binding domain containing, signal transduction associated 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KHDRBS2 mRNA

NCBI chr 9:34,447,023...34,953,684
Ensembl chr 9:34,447,056...34,915,530

G

KH RNA binding domain containing, signal transduction associated 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of KHDRBS3 mRNA

NCBI chr 7:100,837,707...100,995,644
Ensembl chr 7:100,837,934...100,988,460

G

kinesin family member 1B

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of KIF1B mRNA

NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778

G

kinesin family member 3B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KIF3B mRNA

NCBI chr 3:141,758,466...141,798,012
Ensembl chr 3:141,758,466...141,797,963

G

KIT proto-oncogene receptor tyrosine kinase

decreases expression

Maneb results in decreased expression of KIT

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

KLF transcription factor 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of KLF2 mRNA

NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944

G

kelch-like family member 15

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of KLHL15 mRNA

NCBI chr X:58,994,726...59,050,207
Ensembl chr X:58,995,461...59,046,069

G

kelch-like family member 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of KLHL2 mRNA

NCBI chr16:24,860,744...24,973,348
Ensembl chr16:24,860,667...24,973,341

G

kelch-like family member 32

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KLHL32 mRNA

NCBI chr 5:38,321,237...38,568,453
Ensembl chr 5:38,325,543...38,568,650

G

kelch-like family, member 42

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KLHL42 mRNA

NCBI chr 4:179,999,655...180,027,283
Ensembl chr 4:180,004,580...180,027,283

G

KRI1 homolog

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of KRI1 mRNA

NCBI chr 8:19,817,005...19,831,516
Ensembl chr 8:19,817,017...19,831,392

G

laminin subunit alpha 5

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LAMA5 mRNA

NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:167,270,296...167,318,451

G

laminin subunit gamma 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of LAMC2 mRNA

NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200

G

ligand dependent nuclear receptor corepressor-like

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LCORL mRNA

NCBI chr14:65,271,339...65,407,732
Ensembl chr14:65,271,135...65,404,174

G

lactate dehydrogenase A

increases activity

Maneb results in increased activity of LDHA protein

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

LIF receptor subunit alpha

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of LIFR mRNA

NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699

G

LIM domain kinase 2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of LIMK2 mRNA

NCBI chr14:78,208,182...78,286,106
Ensembl chr14:78,218,063...78,286,007

G

lin-7 homolog A, crumbs cell polarity complex component

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LIN7A mRNA

NCBI chr 7:42,586,704...42,742,609
Ensembl chr 7:42,586,719...42,730,550

G

leishmanolysin like peptidase

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of LMLN mRNA

NCBI chr11:67,656,241...67,725,889
Ensembl chr11:67,658,152...67,724,243

G

LIM domain only 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LMO3 mRNA

NCBI chr 4:171,234,686...171,297,677
Ensembl chr 4:171,234,696...171,292,222

G

loricrin cornified envelope precursor protein

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of LORICRIN mRNA

NCBI chr 2:177,558,062...177,560,960
Ensembl chr 2:177,558,252...177,559,807

G

lipoprotein lipase

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

leucine rich repeat and fibronectin type III domain containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LRFN1 mRNA

NCBI chr 1:83,742,442...83,761,450
Ensembl chr 1:83,682,964...83,761,449

G

leucine rich repeat and fibronectin type III domain containing 5

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of LRFN5 mRNA

NCBI chr 6:79,466,403...79,822,821
Ensembl chr 6:79,467,961...79,822,815

G

LDL receptor related protein 4

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of LRP4 mRNA

NCBI chr 3:77,429,600...77,483,593
Ensembl chr 3:77,429,798...77,483,593

G

leucine rich repeat containing 17

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of LRRC17 mRNA

NCBI chr 4:13,501,428...13,531,845
Ensembl chr 4:13,501,436...13,531,845

G

leucine rich repeat containing 24

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LRRC24 mRNA

NCBI chr 7:108,437,296...108,444,561
Ensembl chr 7:108,437,296...108,444,438

G

leucine rich repeat containing 41

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of LRRC41 mRNA

NCBI chr 5:129,554,547...129,575,450
Ensembl chr 5:129,554,547...129,575,449

G

leucine rich repeat containing 4C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LRRC4C mRNA

NCBI chr 3:82,305,495...83,684,039
Ensembl chr 3:83,483,851...83,687,774

G

leucine rich repeat containing 7

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of LRRC7 mRNA

NCBI chr 2:247,146,616...247,634,945
Ensembl chr 2:247,147,752...247,634,547

G

leucine-rich repeat kinase 2

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5R1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5RAP1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CHRM2 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of EFNB1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of FEZ1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NDP mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NRG1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX6 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of POU3F3 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; LRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]
3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein]; [Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein]; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein]

PMID:23017109 PMID:34897981

NCBI chr 7:122,826,696...122,987,711
Ensembl chr 7:122,826,696...122,987,703

G

leucine rich repeat neuronal 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of LRRN2 mRNA

NCBI chr13:44,321,944...44,382,454
Ensembl chr13:44,321,364...44,382,482

G

leucine rich repeat neuronal 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LRRN3 mRNA

NCBI chr 6:58,489,060...58,520,322
Ensembl chr 6:58,489,010...58,520,330

G

leucine rich repeat transmembrane neuronal 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of LRRTM3 mRNA

NCBI chr20:24,515,627...24,689,669
Ensembl chr20:24,515,627...24,689,669

G

LSM11, U7 small nuclear RNA associated

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LSM11 mRNA

NCBI chr10:30,367,841...30,385,956
Ensembl chr10:30,370,727...30,385,944

G

latent transforming growth factor beta binding protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LTBP1 mRNA

NCBI chr 6:20,029,629...20,425,339
Ensembl chr 6:20,029,629...20,425,349

G

lymphocyte antigen 6 family member A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LY6A mRNA

NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981

G

Ly6/neurotoxin 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of LYNX1 mRNA

NCBI chr 7:106,632,800...106,638,003
Ensembl chr 7:106,632,797...106,638,023

G

Ly6/Plaur domain containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of LYPD1 mRNA

NCBI chr13:37,326,459...37,368,515
Ensembl chr13:37,326,464...37,368,493

G

leucine zipper tumor suppressor 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of LZTS1 mRNA

NCBI chr16:20,542,756...20,598,204
Ensembl chr16:20,542,809...20,598,203

G

microtubule-actin crosslinking factor 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of MACF1 mRNA

NCBI chr 5:135,623,734...135,949,097
Ensembl chr 5:135,623,742...135,945,905

G

MAP-kinase activating death domain

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MADD mRNA

NCBI chr 3:77,114,330...77,157,865
Ensembl chr 3:77,114,314...77,157,701

G

microtubule-associated protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA]

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

mitogen activated protein kinase kinase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MAP2K4 mRNA

NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993

G

mitogen-activated protein kinase kinase 6

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA]

NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293

G

mitogen activated protein kinase kinase kinase 7

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MAP3K7 mRNA

NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597

G

microtubule-associated protein 9

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MAP9 mRNA

NCBI chr 2:167,708,661...167,743,927
Ensembl chr 2:167,708,765...167,740,736

G

mitogen activated protein kinase 1

multiple interactions

[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen-activated protein kinase 15

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of MAPK15 mRNA

NCBI chr 7:107,694,907...107,714,640
Ensembl chr 7:107,694,964...107,714,645

G

mitogen activated protein kinase 3

multiple interactions

[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MAPK8 mRNA

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

microtubule-associated protein tau

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA]

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

membrane associated ring-CH-type finger 9

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of MARCHF9 mRNA

NCBI chr 7:62,879,017...62,882,495
Ensembl chr 7:62,879,018...62,882,495

G

MBL associated serine protease 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MASP1 mRNA

NCBI chr11:77,334,794...77,405,271
Ensembl chr11:77,334,859...77,402,974

G

matrilin 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MATN2 mRNA

NCBI chr 7:65,494,996...65,644,613
Ensembl chr 7:65,494,834...65,645,113

G

Mab-21 domain containing 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MB21D2 mRNA

NCBI chr11:71,825,748...71,924,770
Ensembl chr11:71,825,748...71,924,769

G

methyl-CpG binding domain protein 3

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of MBD3 mRNA; [Paraquat co-treated with Maneb] results in increased expression of MBD3 mRNA

NCBI chr 7:9,312,961...9,320,166
Ensembl chr 7:9,313,098...9,320,165

G

metallo-beta-lactamase domain containing 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MBLAC2 mRNA

NCBI chr 2:11,986,075...12,028,882
Ensembl chr 2:11,986,027...12,030,950

G

muscleblind-like splicing regulator 1

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of MBNL1 mRNA

NCBI chr 2:144,639,819...144,814,395
Ensembl chr 2:144,670,285...144,814,368

G

membrane bound O-acyltransferase domain containing 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of MBOAT2 mRNA

NCBI chr 6:41,471,135...41,597,599
Ensembl chr 6:41,471,161...41,593,485

G

MCF.2 cell line derived transforming sequence-like

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MCF2L mRNA

NCBI chr16:76,507,133...76,652,893
Ensembl chr16:76,507,133...76,652,733

G

MCL1 apoptosis regulator, BCL2 family member

increases expression
multiple interactions

Maneb results in increased expression of MCL1 protein
[Paraquat co-treated with Maneb] results in increased expression of MCL1 protein

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

minichromosome maintenance complex component 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MCM6 mRNA

NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960

G

multiple C2 and transmembrane domain containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MCTP1 mRNA

NCBI chr 2:6,071,408...6,761,833
Ensembl chr 2:6,065,808...6,761,833

G

MAM domain containing glycosylphosphatidylinositol anchor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MDGA1 mRNA

NCBI chr20:7,900,327...7,964,309
Ensembl chr20:7,904,358...7,963,471

G

MDM4 regulator of p53

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of MDM4 mRNA

NCBI chr13:44,432,596...44,516,165
Ensembl chr13:44,406,213...44,474,226

G

malic enzyme 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of ME3 mRNA

NCBI chr 1:143,534,024...143,735,551
Ensembl chr 1:143,534,139...143,733,132

G

MTOR associated protein, eak-7 homolog

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of TLDC1 mRNA

NCBI chr19:47,813,899...47,836,830
Ensembl chr19:47,811,416...47,841,278

G

myocyte enhancer factor 2C

multiple interactions

[Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased metabolism of MEF2C protein; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased metabolism of MEF2C protein

NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880

G

multiple EGF-like-domains 9

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MEGF9 mRNA

NCBI chr 5:83,993,565...84,105,622
Ensembl chr 5:83,993,565...84,105,622

G

Meis homeobox 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MEIS3 mRNA

NCBI chr 1:76,861,267...76,872,691
Ensembl chr 1:76,861,924...76,872,691

G

milk fat globule EGF and factor V/VIII domain containing

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of MFGE8 mRNA

NCBI chr 1:133,064,665...133,080,069
Ensembl chr 1:133,064,665...133,080,073

G

major facilitator superfamily domain containing 4A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MFSD4A mRNA

NCBI chr13:43,469,488...43,510,467
Ensembl chr13:43,469,488...43,510,467

G

MGAT4 family, member C

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MGAT4C mRNA

NCBI chr 7:36,709,564...37,485,810
Ensembl chr 7:37,260,321...37,474,571

G

microsomal glutathione S-transferase 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MGST3 mRNA

NCBI chr13:79,526,541...79,547,479
Ensembl chr13:79,526,541...79,547,411

G

microtubule associated monooxygenase, calponin and LIM domain containing 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MICAL3 mRNA

NCBI chr 4:154,152,776...154,353,274
Ensembl chr 4:154,153,834...154,302,590

G

marker of proliferation Ki-67

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MKI67 mRNA

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

metallophosphoesterase domain containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MPPED1 mRNA

NCBI chr 7:114,932,221...115,011,797
Ensembl chr 7:114,944,764...115,011,787

G

mannose receptor, C type 1

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of MRC1 mRNA

NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857

G

mitochondrial ribosomal protein L15

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of MRPL15 mRNA

NCBI chr 5:14,729,961...14,741,276
Ensembl chr 5:14,729,979...14,741,276

G

myocardin related transcription factor B

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of MRTFB mRNA

NCBI chr10:1,116,315...1,278,106
Ensembl chr10:1,116,310...1,277,897

G

metallothionein 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of MT1 mRNA

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049

G

microtubule crosslinking factor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MTCL1 mRNA

NCBI chr 9:106,305,282...106,441,782
Ensembl chr 9:106,321,098...106,442,203

G

methylenetetrahydrofolate reductase

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of MTHFR mRNA

NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797

G

mechanistic target of rapamycin kinase

multiple interactions
increases expression

[Maneb co-treated with Paraquat] results in decreased expression of MTOR mRNA; [Paraquat co-treated with Maneb] results in increased expression of MTOR protein; Maneb promotes the reaction [Paraquat results in increased expression of MTOR protein]; Paraquat promotes the reaction [Maneb results in increased expression of MTOR protein]

PMID:22292029 PMID:26884967 PMID:36117858

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

mucin 6, oligomeric mucus/gel-forming

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of MUC6 mRNA

NCBI chr 1:196,726,678...196,764,842
Ensembl chr 1:196,726,807...196,764,842

G

myeloid-associated differentiation marker-like 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MYADML2 mRNA

NCBI chr10:105,922,557...105,927,867
Ensembl chr10:105,925,947...105,927,575

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of MYC protein

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

MYCN proto-oncogene, bHLH transcription factor

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MYCN mRNA

NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590

G

myosin heavy chain 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of MYH7 mRNA

NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217

G

myosin light chain 9

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MYL9 mRNA

NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333

G

myosin regulatory light chain interacting protein

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of MYLIP mRNA

NCBI chr17:19,286,649...19,308,295
Ensembl chr17:19,286,650...19,308,295

G

N-6 adenine-specific DNA methyltransferase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of N6AMT1 mRNA

NCBI chr11:26,584,750...26,597,790
Ensembl chr11:26,584,724...26,608,248

G

N(alpha)-acetyltransferase 25, NatB auxiliary subunit

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NAA25 mRNA

NCBI chr12:35,098,256...35,150,498
Ensembl chr12:35,098,075...35,150,467

G

nucleosome assembly protein 1-like 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NAP1L2 mRNA

NCBI chr X:68,174,051...68,176,449
Ensembl chr X:68,173,987...68,176,666

G

nucleosome assembly protein 1-like 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NAP1L3 mRNA

NCBI chr X:88,347,595...88,350,393
Ensembl chr X:88,347,598...88,350,393

G

neurobeachin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NBEA mRNA

NCBI chr 2:139,780,021...140,338,639
Ensembl chr 2:139,780,021...140,340,584

G

neutrophil cytosolic factor 1

multiple interactions

[Maneb co-treated with Paraquat] affects the localization of NCF1 protein; [Maneb co-treated with Paraquat] results in increased expression of NCF1 protein; [Paraquat co-treated with Maneb] results in increased expression of NCF1 protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NCF1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] affects the localization of NCF1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein]

PMID:28202386 PMID:29568078 PMID:32375810 PMID:34052309

NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646

G

nuclear receptor coactivator 7

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NCOA7 mRNA

NCBI chr 1:26,856,228...27,016,950
Ensembl chr 1:26,856,530...27,015,871

G

neuron-derived neurotrophic factor

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of NDNF mRNA

NCBI chr 4:94,944,392...94,981,871
Ensembl chr 4:94,944,360...94,981,873

G

norrin cystine knot growth factor NDP

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NDP mRNA

NCBI chr X:5,796,487...5,820,934
Ensembl chr X:5,796,487...5,820,934

G

N-deacetylase and N-sulfotransferase 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NDST3 mRNA

NCBI chr 2:211,702,728...211,868,159
Ensembl chr 2:211,704,898...211,854,584

G

NECAP endocytosis associated 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NECAP1 mRNA

NCBI chr 4:156,103,935...156,119,068
Ensembl chr 4:156,103,988...156,119,068

G

neurofilament medium chain

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NEFM mRNA

NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755

G

nuclear envelope integral membrane protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NEMP1 mRNA

NCBI chr 7:63,514,025...63,538,791
Ensembl chr 7:63,479,951...63,534,602

G

neuroepithelial cell transforming 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of NET1 mRNA

NCBI chr17:66,341,251...66,370,445
Ensembl chr17:66,340,728...66,370,441

G

neuralized E3 ubiquitin protein ligase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NEURL1A mRNA

NCBI chr 1:246,066,830...246,152,890
Ensembl chr 1:246,067,100...246,152,903

G

neuronal differentiation 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NEUROD1 mRNA

NCBI chr 3:64,359,554...64,363,526
Ensembl chr 3:64,359,395...64,363,649

G

neuronal differentiation 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NEUROD2 mRNA

NCBI chr10:83,323,801...83,327,986
Ensembl chr10:83,324,442...83,327,986

G

nuclear factor of activated T-cells 5

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of NFAT5 mRNA

NCBI chr19:35,199,737...35,286,675
Ensembl chr19:35,199,016...35,286,675

G

NFE2 like bZIP transcription factor 2

increases expression
increases response to substance
multiple interactions

[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of PRDX1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXN1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXNRD1 mRNA; Maneb results in increased expression of NFE2L2 protein
NFE2L2 gene mutant form results in increased susceptibility to Maneb
[NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased abundance of Glutathione; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of GSR protein; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of HMOX1 protein; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in increased abundance of Manganese; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in increased abundance of Thiobarbituric Acid Reactive Substances; NFE2L2 gene mutant form inhibits the reaction [Maneb results in increased expression of GPX4 mRNA]

PMID:21402726 PMID:23764462

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor I/B

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of NFIB mRNA

NCBI chr 5:96,759,208...96,974,001
Ensembl chr 5:96,764,653...96,975,479

G

nuclear factor kappa B subunit 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions

[Maneb co-treated with Paraquat] results in increased phosphorylation of and results in decreased expression of NFKBIA protein; [Paraquat co-treated with Maneb] results in increased degradation of and results in increased phosphorylation of NFKBIA protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of and results in decreased expression of NFKBIA protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased degradation of and results in increased phosphorylation of NFKBIA protein]

PMID:28202386 PMID:29568078

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NHP2 ribonucleoprotein

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of NHP2 mRNA

NCBI chr10:35,877,057...35,880,399
Ensembl chr10:35,877,054...35,882,545

G

ninein-like

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NINL mRNA

NCBI chr 3:139,748,353...139,814,683
Ensembl chr 3:139,748,355...139,814,622

G

NIPA-like domain containing 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NIPAL3 mRNA

NCBI chr 5:147,687,310...147,725,838
Ensembl chr 5:147,685,288...147,726,351

G

NIPBL, cohesin loading factor

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of NIPBL mRNA

NCBI chr 2:57,399,443...57,586,770
Ensembl chr 2:57,399,445...57,565,899

G

neuroligin 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NLGN1 mRNA

NCBI chr 2:108,256,236...109,181,530
Ensembl chr 2:108,257,824...109,002,464

G

NLR family, pyrin domain containing 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of NLRP3 protein; [Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NLRP3 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]

PMID:32375810 PMID:34052309

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nicotinamide nucleotide adenylyltransferase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NMNAT1 mRNA

NCBI chr 5:159,910,242...159,928,201
Ensembl chr 5:159,910,242...159,928,180

G

nicotinamide nucleotide adenylyltransferase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NMNAT2 mRNA

NCBI chr13:65,105,950...65,277,350
Ensembl chr13:65,105,950...65,278,484

G

noggin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NOG mRNA

NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339

G

nucleolar protein 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NOL4 mRNA

NCBI chr18:13,932,499...14,294,873
Ensembl chr18:13,932,510...14,296,286

G

nitric oxide synthase 2

multiple interactions
increases expression

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; [Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA; [Maneb co-treated with Paraquat] results in increased expression of NOS2 protein; [Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA; [Paraquat co-treated with Maneb] results in increased expression of NOS2 protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Genistein inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; pimagedine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; prolinedithiocarbamate inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]
[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of NOS2 mRNA]

PMID:20455021 PMID:23159886 PMID:23963992 PMID:28202386 PMID:29568078 More...

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NOVA alternative splicing regulator 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NOVA1 mRNA

NCBI chr 6:63,780,105...63,905,567
Ensembl chr 6:63,783,489...63,906,289

G

NADPH oxidase 1

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA]; diphenyleneiodonium inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA]

NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236

G

neuropeptide S

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of NPS mRNA

NCBI chr 1:190,077,040...190,080,821
Ensembl chr 1:190,077,040...190,080,821

G

NAD(P)H quinone dehydrogenase 1

increases expression

[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 2, group F, member 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NR2F2 mRNA

NCBI chr 1:124,008,282...124,022,521
Ensembl chr 1:124,009,181...124,022,031

G

nuclear receptor subfamily 4, group A, member 1

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of NR4A1 mRNA

NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297

G

nuclear receptor subfamily 4, group A, member 2

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of NR4A2 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of NR4A2 protein

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

neuregulin 1

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NRG1 mRNA

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

nuclear receptor interacting protein 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NRIP2 mRNA

NCBI chr 4:161,673,964...161,684,055
Ensembl chr 4:161,639,356...161,684,070

G

neuritin 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NRN1 mRNA

NCBI chr17:28,129,969...28,138,898
Ensembl chr17:28,129,977...28,138,896

G

neurturin

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of NRTN mRNA

NCBI chr 9:1,581,860...1,587,835
Ensembl chr 9:1,581,975...1,583,102

G

netrin 1

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA; [Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA

NCBI chr10:52,899,933...53,098,591
Ensembl chr10:52,899,934...53,085,326

G

netrin 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NTN4 mRNA

NCBI chr 7:28,186,611...28,300,390
Ensembl chr 7:28,186,611...28,300,390

G

netrin G1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NTNG1 mRNA

NCBI chr 2:197,462,785...197,827,681
Ensembl chr 2:197,463,945...197,826,997

G

neurotrophic receptor tyrosine kinase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA]

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

nudix hydrolase 11

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of NUDT10 mRNA

NCBI chr X:16,326,775...16,333,396
Ensembl chr X:16,326,598...16,333,145

G

neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of NYAP1 mRNA

NCBI chr12:18,956,192...18,967,624
Ensembl chr12:18,956,268...18,967,543

G

ornithine decarboxylase antizyme 2

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of OAZ2 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of OAZ2 mRNA]

NCBI chr 8:66,199,694...66,213,513
Ensembl chr 8:66,199,706...66,231,453

G

2-oxoglutarate and iron-dependent oxygenase domain containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of OGFOD1 mRNA

NCBI chr19:10,945,031...10,974,602
Ensembl chr19:10,946,018...10,975,119

G

one cut homeobox 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of ONECUT2 mRNA

NCBI chr18:57,831,647...57,890,884
Ensembl chr18:57,832,111...57,879,629

G

oxysterol binding protein-like 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of OSBPL6 mRNA

NCBI chr 3:61,343,776...61,541,170
Ensembl chr 3:61,343,809...61,537,102

G

pyrimidinergic receptor P2Y4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of P2RY4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of P2RY4 mRNA]

NCBI chr X:65,681,680...65,717,404
Ensembl chr X:65,683,232...65,721,748

G

p21 (RAC1) activated kinase 6

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PAK6 mRNA

NCBI chr 3:105,638,248...105,674,399
Ensembl chr 3:105,638,653...105,672,975

G

peptidase domain containing associated with muscle regeneration 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PAMR1 mRNA

NCBI chr 3:88,889,061...88,988,615
Ensembl chr 3:88,889,046...88,988,606

G

Parkinsonism associated deglycase

multiple interactions
decreases activity

3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein]; [Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein]; Maneb results in decreased activity of and results in increased oxidation of PARK7 protein; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein]
Maneb results in decreased activity of PARK7 protein

PMID:34897981 PMID:36842454

NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970

G

prostate androgen-regulated mucin-like protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PARM1 mRNA

NCBI chr14:16,468,309...16,577,339
Ensembl chr14:16,468,459...16,577,314

G

paired box 5

multiple interactions

[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX5 mRNA

NCBI chr 5:58,763,334...58,945,719
Ensembl chr 5:58,765,036...58,944,326

G

paired box 6

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX6 mRNA

NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014

G

pterin-4 alpha-carbinolamine dehydratase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PCBD1 mRNA

NCBI chr20:29,037,545...29,044,322
Ensembl chr20:28,953,864...29,044,292
Ensembl chr20:28,953,864...29,044,292

G

protocadherin 11 X-linked

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PCDH11X mRNA

NCBI chr X:86,058,348...86,751,078
Ensembl chr X:86,058,394...86,747,036

G

protocadherin 18

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PCDH18 mRNA

NCBI chr 2:133,831,996...133,845,992
Ensembl chr 2:133,832,001...133,845,883

G

protocadherin 19

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PCDH19 mRNA

NCBI chr X:96,767,686...96,873,477
Ensembl chr X:96,771,947...96,873,524

G

protocadherin 7

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PCDH7 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PCDH7 mRNA]

NCBI chr14:52,471,801...52,901,696
Ensembl chr14:52,475,610...52,902,051
Ensembl chr14:52,475,610...52,902,051

G

protocadherin 9

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PCDH9 mRNA

NCBI chr15:69,340,108...70,237,531
Ensembl chr15:69,340,645...70,237,538

G

protocadherin beta 20

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PCDHB14 mRNA

NCBI chr18:29,211,878...29,215,272
Ensembl chr18:29,211,883...29,215,258

G

polycomb group ring finger 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PCGF2 mRNA

NCBI chr10:82,682,563...82,694,563
Ensembl chr10:82,683,553...82,693,406

G

PCNA clamp associated factor

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PCLAF mRNA

NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994
Ensembl chr 8:66,420,587...66,432,994

G

proliferating cell nuclear antigen

multiple interactions

3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of PCNA protein]; [Paraquat co-treated with Maneb] results in decreased expression of PCNA protein

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

Purkinje cell protein 2

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of PCP2 mRNA

NCBI chr12:1,681,659...1,683,899
Ensembl chr12:1,681,659...1,683,899

G

programmed cell death 10

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of PDCD10 mRNA

NCBI chr 2:160,303,465...160,346,086
Ensembl chr 2:160,303,449...160,346,018

G

phosphodiesterase 10A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PDE10A mRNA

NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563

G

phosphodiesterase 1B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PDE1B mRNA; [Maneb co-treated with Paraquat] results in increased expression of PDE1B mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PDE1B mRNA]

PMID:23963992 PMID:36117858

NCBI chr 7:134,627,378...134,654,581
Ensembl chr 7:134,627,322...134,654,580

G

phosphodiesterase 2A

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PDE2A mRNA

NCBI chr 1:155,823,590...155,915,434
Ensembl chr 1:155,813,180...155,915,434

G

platelet derived growth factor receptor alpha

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PDGFRA mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PDGFRA mRNA]

NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335

G

pyruvate dehydrogenase E1 subunit alpha 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PDHA1 mRNA; [Maneb co-treated with Paraquat] results in increased expression of PDHA1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PDHA1 protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PDHA1 mRNA]

PMID:23562983 PMID:23963992

NCBI chr X:34,700,481...34,714,309
Ensembl chr X:34,700,409...34,714,311

G

prodynorphin

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of PDYN

NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334

G

PDZ domain containing 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PDZD2 mRNA

NCBI chr 2:61,384,614...61,770,516
Ensembl chr 2:61,386,381...61,770,524

G

PDZ domain containing 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PDZD4 mRNA; [Maneb co-treated with Paraquat] results in increased expression of PDZD4 mRNA

NCBI chr X:151,530,390...151,560,779
Ensembl chr X:151,530,390...151,560,826

G

platelet endothelial aggregation receptor 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PEAR1 mRNA

NCBI chr 2:173,206,298...173,234,106
Ensembl chr 2:173,207,664...173,227,440

G

phosphatidylethanolamine binding protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PEBP1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PEBP1 protein]

NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862

G

paternally expressed 10

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PEG10 mRNA

NCBI chr 4:32,842,441...32,855,639
Ensembl chr 4:32,848,493...32,852,621

G

p53 apoptosis effector related to PMP22

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PERP mRNA

NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PFKFB4 mRNA

NCBI chr 8:109,643,558...109,687,006
Ensembl chr 8:109,643,937...109,685,634

G

post-GPI attachment to proteins inositol deacylase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PGAP1 mRNA

NCBI chr 9:55,975,574...56,044,325
Ensembl chr 9:55,975,667...56,044,464

G

phosphoglucomutase 2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PGM2 mRNA

NCBI chr14:44,166,314...44,199,828
Ensembl chr14:44,164,425...44,199,967

G

phosphoglucomutase 2-like 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PGM2L1 mRNA

NCBI chr 1:154,571,410...154,620,901
Ensembl chr 1:154,571,766...154,620,902

G

phosphatidylglycerophosphate synthase 1

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of PGS1 mRNA

NCBI chr10:103,214,635...103,250,254
Ensembl chr10:103,214,646...103,250,254

G

phosphatidylinositol glycan anchor biosynthesis, class C

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of PIGC mRNA

NCBI chr13:74,343,619...74,346,148
Ensembl chr13:74,296,854...74,346,211

G

phosphatidylinositol glycan anchor biosynthesis, class W

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PIGW mRNA

NCBI chr10:69,746,996...69,782,656
Ensembl chr10:69,748,789...69,790,475

G

phosphoinositide-3-kinase regulatory subunit 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PIK3R3 mRNA

NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583

G

PITPNM family member 3

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PITPNM3 mRNA

NCBI chr10:56,674,697...56,766,552
Ensembl chr10:56,676,261...56,766,584

G

cAMP-dependent protein kinase inhibitor beta

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PKIB mRNA

NCBI chr20:36,965,172...37,062,190
Ensembl chr20:36,905,340...37,062,187

G

phospholipase C, epsilon 1

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of PLCE1 mRNA

NCBI chr 1:236,243,445...236,552,571
Ensembl chr 1:236,244,683...236,551,438

G

pleckstrin homology and RUN domain containing M2

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PLEKHM2 mRNA

NCBI chr 5:153,939,582...153,978,625
Ensembl chr 5:153,940,262...153,978,689

G

phospholipid phosphatase 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PLPP4 mRNA

NCBI chr 1:183,829,794...183,959,319
Ensembl chr 1:183,830,409...183,959,319

G

plexin A1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PLXNA1 mRNA

NCBI chr 4:121,737,934...121,782,901
Ensembl chr 4:121,737,945...122,024,196

G

plexin C1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PLXNC1 mRNA

NCBI chr 7:29,390,038...29,543,985
Ensembl chr 7:29,390,048...29,543,779

G

phorbol-12-myristate-13-acetate-induced protein 1

increases expression

Maneb results in increased expression of PMAIP1 mRNA; Maneb results in increased expression of PMAIP1 protein

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

prepronociceptin

multiple interactions

[Paraquat co-treated with Maneb] results in increased expression of PNOC

NCBI chr15:39,624,635...39,652,463
Ensembl chr15:39,624,641...39,651,867

G

RNA polymerase I subunit B

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of POLR1B mRNA

NCBI chr 3:116,333,910...116,358,385
Ensembl chr 3:116,333,889...116,358,379

G

RNA polymerase I and III subunit C

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of POLR1C mRNA

NCBI chr 9:14,735,740...14,739,852
Ensembl chr 9:14,735,714...14,739,852

G

RNA polymerase II, I and III subunit K

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of POLR2K mRNA

NCBI chr 7:67,347,118...67,359,466
Ensembl chr 7:67,356,113...67,357,668

G

POM121 transmembrane nucleoporin

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of POM121 mRNA

NCBI chr12:21,273,713...21,294,299
Ensembl chr12:21,276,913...21,294,294

G

POU class 3 homeobox 3

multiple interactions

[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of POU3F3 mRNA

NCBI chr 9:44,945,872...44,948,998
Ensembl chr 9:44,945,872...44,948,992

G

PTPRF interacting protein alpha 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PPFIA3 mRNA; [Maneb co-treated with Paraquat] results in increased expression of PPFIA3 mRNA

NCBI chr 1:95,817,110...95,845,950
Ensembl chr 1:95,817,110...95,845,798

G

diphosphoinositol pentakisphosphate kinase 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PPIP5K1 mRNA

NCBI chr 3:108,284,120...108,327,683
Ensembl chr 3:108,284,120...108,323,428

G

protein phosphatase 1, regulatory subunit 3F

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PPP1R3F mRNA

NCBI chr X:14,915,740...14,945,249
Ensembl chr X:14,929,323...14,945,193

G

protein phosphatase 2, regulatory subunit B, gamma

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PPP2R2C mRNA

NCBI chr14:73,846,547...73,931,489
Ensembl chr14:73,846,547...73,931,864

G

protein phosphatase 6, regulatory subunit 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PPP6R1 mRNA

NCBI chr 1:69,190,856...69,217,598
Ensembl chr 1:69,189,822...69,216,272

G

peptidylprolyl isomerase domain and WD repeat containing 1

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PPWD1 mRNA

NCBI chr 2:35,337,301...35,360,661
Ensembl chr 2:35,335,962...35,360,460

G

PR/SET domain 15

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PRDM15 mRNA

NCBI chr11:37,164,608...37,225,172
Ensembl chr11:37,165,575...37,222,207

G

peroxiredoxin 1

increases expression

[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of PRDX1 mRNA

NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856

G

peroxiredoxin 3

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]

NCBI chr 1:260,001,642...260,014,064
Ensembl chr 1:260,001,637...260,014,111

G

protein kinase cAMP-activated catalytic subunit alpha

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of PRKACA mRNA; [Paraquat co-treated with Maneb] results in decreased expression of PRKACA protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of PRKACA mRNA]

PMID:27460631 PMID:33368748

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

protein kinase C, zeta

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of PRKCZ mRNA

NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367

G

parkin RBR E3 ubiquitin protein ligase

multiple interactions

3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased nitrosation of PRKN protein]; [Paraquat co-treated with Maneb] results in increased expression of PRKN protein; [Paraquat co-treated with Maneb] results in increased nitrosation of PRKN protein

PMID:22563483 PMID:23985028

NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555

G

prolactin

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of PRL mRNA

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

protein arginine methyltransferase 8

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PRMT8 mRNA

NCBI chr 4:160,535,813...160,618,193
Ensembl chr 4:160,535,813...160,617,930

G

proline rich 7 (synaptic)

multiple interactions

[Paraquat co-treated with Maneb] affects the expression of PRR7 mRNA

NCBI chr17:9,164,375...9,173,669
Ensembl chr17:9,165,269...9,172,536

G

proline-rich transmembrane protein 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PRRT1 mRNA

NCBI chr20:4,117,957...4,121,643
Ensembl chr20:4,117,957...4,121,600

G

prosaposin

multiple interactions

[Paraquat co-treated with Maneb] results in decreased expression of PSAP mRNA

NCBI chr20:28,214,229...28,240,501
Ensembl chr20:28,214,271...28,240,498

G

presenilin 1

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA]

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

G

proteasome 20S subunit beta 1

multiple interactions

Maneb inhibits the reaction [Paraquat results in decreased expression of PSMB1 mRNA]

NCBI chr 1:56,442,432...56,463,544
Ensembl chr 1:56,420,618...56,463,560

G

proteasome 26S subunit, ATPase 4

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PSMC4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PSMC4 mRNA]
[Paraquat co-treated with Maneb] results in decreased expression of PSMC4 mRNA

PMID:23963992 PMID:26498265

NCBI chr 1:83,349,127...83,357,497
Ensembl chr 1:83,348,592...83,357,494

G

patched domain containing 4

multiple interactions

[Maneb co-treated with Paraquat] results in increased expression of PTCHD4 mRNA

NCBI chr 9:18,462,934...18,666,272
Ensembl chr 9:18,463,737...18,665,705

G

protein tyrosine kinase 2 beta

multiple interactions

[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of PTK2B protein modified form; [Maneb co-treated with Paraquat] results in decreased expression of PTK2B mRNA

PMID:19883720 PMID:36117858

NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282

G

protein tyrosine phosphatase, non-receptor type 4

affects activity

Maneb affects the activity of PTPN4 protein

NCBI chr13:30,772,012...30,952,340
Ensembl chr13:30,776,682...30,952,170

G

protein tyrosine phosphatase, non-receptor type 9

affects activity

Maneb affects the activity of PTPN9 protein

NCBI chr 8:57,391,290...57,472,352
Ensembl chr 8:57,391,259...57,470,952

G

protein tyrosine phosphatase, receptor type, F

multiple interactions

[Maneb co-treated with Paraquat] results in decreased expression of PTPRF mRNA

NCBI chr 5:131,741,959...131,824,000
Ensembl chr 5:131,742,754...131,810,023